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1 Abbrevations 
 
AA – arachidonic acid 
Ab – antibody 
AC – adenyl cyclase 
A.D. – anno domini 
Ag – antigen 
Akt – protein kinase B 
AMC – ascites mononuclear cells 
AP-1 – activator protein 1 
APC (cell) – antigen presenting cell 
APC (dye) – allophycocyanin 
APC (gene/protein) – adenomatous polyposis coli 
ASA - acetylsalicylic acid 
ATC – anatomical therapeutic chemical 
classification 
Bcl-2 – B cell lymphoma 2 
bGFG – basic fibroblast growth factor 
BRCA1 – breast cancer type 1 
BRCA2 – breast cancer type 2 
cAMP – cyclic adenosine monophosphate 
CA125 – cancer antigen 125 
CD – cluster of differentiation 
CD25 - alpha chain of the IL-2 receptor 
CD45RO - Protein tyrosine phosphatase, receptor 
type, C 
CD71 - transferrin receptor protein 1 
CD95 - tumor necrosis factor receptor 
CD127 – interleukin-7 receptor 
CD147 - basigin/emmprin 
CD148 - receptor-type tyrosine-protein 
phosphates-eta superfamily member 6 
CEA – carcinoembryonic antigen 
CFSE – carboxyfluorescein diacetate succinimidyl 
ester 
CI – confidence interval 
CIMP – CpG island methylator phenotype 
CIN – chromosomal instability 
CNR – Cancer Registry of Norway 
CO2 – carbon dioxide 
COX – cyclooxygenase 
CRC – colorectal cancer 
CRLM – colorectal cancer liver metastasis 
CRP – C reactive protein 
Csk – C-terminal Src kinase 
CT – computed tomography 
CTL – cytotoxic T lymphocyte 
CTLA-4 – cytotoxic T lymphocyte antigen-4 
DC – dendritic cell 
DDD – defined daily dose 
DNA – deoxyribonucleic acid 
EDTA - ethylenediaminetetraacetic acid 
EGFR – epidermal growth factor receptor 
EP – E Prostanoid receptor 
ERK – extracellular signal-regulated kinases 
FACS - fluorescent activated cell sorting 
FAP – familial adenomatous polyposis 
FasL – Fas ligand 
Fcm - flow cytometry 
FCS – fetal calf serum 
FIGO – International Federation of Gynecology 
and Obstetrics 
FITC - fluorescein isothiocyanate 
FKH – forkhead 
FoxP3 – forkhead box protein 3 
GITR – glucocorticoid-induced TNF receptor 
GM-CSF – granulocyte-macrophage colony-
stimulating factor 3 
GPCR – G protein coupled receptor 
Her-2 – human epidermal growth factor receptor 2 
HE4 – human epididymis 4 
HLA – human leukocyte antigen 
HNPCC – hereditary non-polyposis colon cancer 
HR – hazard ratio 
ICD-O-03 - International Classification of 
Diseases for Oncology, 3rd edition 
ICD-10 – International Classification of Diseases, 
10th edition 
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IDO - indoleamine 2,3-dioxygenase 
IFN – interferon 
IL – interleukin 
IL-8 – neutrophil chemotactic factor 
IL-10 - human cytokine synthesis inhibitory factor  
IPEX - immunodysregulation polyendocrinopathy 
enteropathy X-linked syndrome 
ITAM – immunoreceptor tyrosine-based activation 
motifs 
JAK – janus kinase 
K-ras – Kirsten rat sarcoma viral oncogene 
homolog 
LAG-3 – lymphocyte activation gene 3 
LC – liquid chromatography 
Lck - lymphocyte-specific protein tyrosine kinase 
LPS - lipopolysaccharide 
MAPK – mitogen-activated protein kinase 
MHC – major histocompatibility complex 
miRNA – micro ribo nucleic acid 
MMR – mismatch repair gene 
MRI – magnetic resonance imaging 
mRNA – messenger ribo nucleic acid 
MS – mass spectrometry 
MSI – microsatellite instability 
NFAT – nuclear factor of activated cells 
NFκB – nuclear factor kappa B 
NK – natural killer 
NorPD – Norwegian Prescription Database 
NY-ESO-1 - New York esophageal squamous cell 
carcinoma 1 
OC – ovarian cancer 
PAMP – pathogen-associated molecular patterns 
PBMC – peripheral blood mononuclear cells 
PBS - phosphate-buffered saline 
PD-1 – programmed death 1 
PE - phycoerythrin 
PerCP - peridinin chlorophyll protein 
PET – positron emission tomography 
PFA – paraformaldehyde 
PG – prostaglandin 
PI - phosphoinositide 
PI3K – phosphoinositide 3-kinase 
PLD – pegylated liposomal doxorubicin 
PMA – phorbol myristate acetate 
PTEN - phosphatase and tensin homolog 
PTK – protein tyrosine kinase 
p53 – protein 53 
RAS – rat sarcoma 
RCMRE - Regional Committee for Medical 
Research Ethics 
RAR – retinoid acid receptor 
RFA – radiofrequency ablation 
RCT – randomized controlled trial 
ROME – risk of ovarian malignancy algorithm 
RORC - RAR-related orphan receptor C 
Src – Proto-oncogene tyrosine-protein kinase 
sarcoma 
STAT - Signal Transducer and Activator of 
Transcription 
TAA – tumor associated antigen 
TAMs – tumor associated macrophages 
TCR – T cell receptor 
TGF – tumor growth factor 
Th – T helper 
TNF – tumor necrosis factor 
TNM – tumor, node, metastasis 
Tp53 (gene) – tumor protein 53 
Treg – regulatory T cell 
TXA2 – thromboxane A2VEGF – vascular 
endothelial growth factor 
WHO – world health organization 
Wnt – wingless intergration 1 
XIAP – X-linked inhibitor of apoptosis protein 
Zap70 – ζ-chain-associated protein kinase 
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3 Introduction 
 
Cancer is a leading cause of deaths world-wide, and current research is on-going to develop 
new means of early diagnosis and treatment. Early detection of disease is an important means 
to prolong survival, and several screening programs have been developed with this purpose. 
Traditionally, cancer management has been centered around surgery, radiotherapy and 
chemotherapy, alone or in combination. In recent years, the potential of using the immune 
system to combat tumor development has been launched as a 4th pillar in treatment of cancer 
patients, and cancer immune therapies are now focus of increasing attention. 
Cancer immunology is a growing field that explains some of the complex cellular and 
molecular interplay between tumors and host immunity. The basis for tumor immunology is 
the biological pattern of tumor cells and a functional immune system. The term 
immunogenicity encompasses tumor antigen recognition and actions of cytotoxic killer cells. 
Immunotherapy focuses on essential immunogenic elements to evoke tumor-specific humoral 
and cell-mediated immune response 1, and how to circumvent tumor-induced immune 
suppressive mechanisms. 
In contrast to the anti-tumor immune response, tumors employ several mechanisms to escape 
attack by the immune system, including recruitment of regulatory T cells (Tregs) to foster 
tolerance. In this Thesis we have focused on several aspects of anti-tumor immunity and 
tumor development. Firstly, we have conducted a study to distinguish the characteristics and 
function of Tregs in healthy humans. Regulatory T cells are an important mediator in tumor 
immune evasion, but due to the lack of a distinct surface-marker, they have proven difficult 
to target for immune-regulatory purposes. Furthermore, we have looked into the interplay 
between immune cells and tumor microenvironment in a disease model, specifically in 
human ovarian cancer patients. Ovarian cancer (OC) was chosen as a model due to presence 
of malignant ascites in advanced stages. Malignant ascites fluid from OC patients contains 
cytokines, extracellular matrix components and free-floating immune and tumor cells, and 
represents the tumor microenvironment in a soluble fashion, making it an easily accessible 
model to study anti-tumor immunity. A parallel study was conducted in our lab where the 
cellular compartment of the malignant ascites was assessed, specifically with regards to Tregs 
and tumor-infiltrating and tumor associated lymphocytes 2. My main focus has been 
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characterization of the cell-free ascites, in order to unravel the effect of soluble immune 
mediators in a malignant environment. 
Furthermore, we conducted two observational studies in colorectal patients. One of the 
studies looked into the use of aspirin as a potential treatment/secondary preventive remedy in 
colorectal cancer patients. Aspirin influences both the tumor directly and also the immune 
cells, through inhibition of cyclooxygenase (COX) isoenzymes. COX-2 facilitates the 
accumulation of prostaglandin E2 (PGE2), a known facilitator in tumor development and 
tumor immune evasion. Lastly, we carried out a cohort study regarding novel treatment 
options for colorectal cancer patients with liver metastases. 
3.1 The immune system 
The immune system is the human body’s defense mechanism against invading pathogens 
(virus, bacteria and fungi). Other functions include monitoring tissue homeostasis and to 
preserve the host tissue intact. An immune reaction is the result of interplay between 
numerous defense mechanisms that work in concert and augment individual responses. A 
number of innate properties (specificity, diversity, discrimination, memory and self-limitation) 
are of vital importance for the normal function of the immune systems, and all its components 
are meticulously controlled to secure an equilibrium3. However, autoimmune diseases 
develop when there is immunological overshoot leading to self-attack. Regulatory immune 
mechanisms are thus needed to ensure that appropriate responses are elicited when the host is 
under attack, and to separate self from non-self.  
3.1.1 Innate and adaptive immunity 
When faced with an invading pathogen or tissue damage, the immune system reacts promptly.  
Our innate immune system is the first line of defense, after the outer barrier (skin and mucosa) 
and attacks invading pathogens based on pathogen-associated molecular pattern (PAMP) 
recognition, in an unspecific and “simple” mode. Central effectors include 
monocytes/macrophages, dendritic cells (DCs), granulocytes, natural killer (NK) cells, mast 
cells and soluble parts like complement factors, cytokines and acute phase proteins 4. 
Our innate immunity collaborates with the adaptive immune system in a coordinated manner 
5, as the adaptive system mounts a later, more specific response. The adaptive immunity also 
confers an immunological memory, that enables a much more proficient reaction upon a re-
infection with the same pathogen 6.   
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The main effectors of the adaptive immune system are the B- and T cells. Naïve B cells 
develop in the bone marrow, further advance into isotype-switched memory B cells, and may 
differentiate into immunoglobulin producing plasma cells and produce antibodies that target 
specific antigens. T cells develop in the bone marrow and mature in the thymus, and are 
responsible for cell-mediated immune responses 5. T cell immunological memory is related to 
an increase in the antigen specific cell population with the presence of surface molecules with 
homing properties, thus ensuring a faster and more extensive secondary immune response.  
A prerequisite for an adaptive immune response is presentation of foreign antigens by innate 
immune cells, such as macrophages and dendritic cells.  These antigen presenting cells 
(APCs) bind antigens on their surface receptor, next they engulf and process the antigens, 
before presenting them on major histocompatibility complex (MHC) molecules to T cell 
receptors in germinal centers of lymph nodes. MHC molecules are found in all vertebrates, 
originally identified as an antigen system of the leukocytes, therefore called Human 
Leukocyte Antigen (HLA) in humans. The purpose of MHC antigens is to serve as an identity 
marker on the surface of cells and present foreign antigen peptides (MHC-antigen complex) 
to the T cell receptor (TCR). MHC-class I molecules are expressed on the surface of all 
nucleated cells and present antigens to CD8+ cytotoxic T cells. MHC-class II molecules on 
the other hand, are exclusively expressed on the surface of APC’s, and thus present antigens 
to CD4+  T helper cells 4.  
 
 
  
FIGURE 1: B and T cells develop in the bone marrow and thymus 
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3.1.2 T cell-mediated immunity 
Immunity involves a panoply of different cell types (as mentioned above), but this Thesis 
focuses mainly on CD3+ T lymphocytes which serve to orchestrate most immune responses. 
Depending on the cytokine environment in the lymph node and the specific APC, the T cells 
develop into cytotoxic CD8+ T cells that combat foreign pathogens by killing them directly, 
or CD4+ T helper cells which achieve the same through secretion of chemokines and 
cytokines to recruit other effector immune cells. 
The CD4+  T helper (Th) cells are further divided into subpopulations, including the 
traditional Th1 and Th2 cells, and the more recently discovered Th17, Th9, follicular T 
helper cells (Tfh), Th3, Tr1 and regulatory T cells (Tregs). 
Th1 cells secrete IFN-γ, IL-2 and lymphotoxin (LT) to stimulate macrophages and cytotoxic 
T cells, and trigger subsequent killing of intracellular pathogens or viruses. Th2 cells produce 
IL-4, IL-5 and IL-13, and are important in the activation of B cells and antibody production, 
providing the host with an extracellular immunity. 
Recently, additional T helper subsets have been identified: Th17 cells are IL-17 producing 
CD4+  Th cells, and differentiate under the influence of IL-1 and IL-23 7. Besides IL-17, 
these cells also produce IL-21 and IL-22, protecting surfaces against extracellular bacteria 8. 
In 2009 the idea of a Th 9 cells was launched. Veldhoen et al. proposed that the new addition 
to the Th cell-family was in fact “reprogrammed” Th2 cells that lose their characteristic 
profile under TGF-β influence, switching to IL-9 production 9. Follicular T helper (Tfh) cells 
are an antigen experienced CD4+ T cells found in abundance in the B follicles of secondary 
lymphoid organs, such as spleen and lymph nodes. The Tfh cells mediate transition of B cells 
to antibody-producing plasma cells. Th3- and Tr1 cells are subsets of regulatory T cells 
(Tregs) that can suppress immune responses. 
3.1.3 T cell activation 
The T cell receptor (TCR) complex consists of two functional parts – the heterodimeric 
glycoprotein of one α- and β-chain, and the CD3 and ζ-chain homodimer. The TCR is subject 
to random gene rearrangement in individual developing T cells, thus providing the huge 
diversity in T cell repertoire. T cells require two signals to reach a state of full activation. 
Initially, the TCR needs to engage a MHC/peptide complex as presented by antigen 
presenting cells (APC), to determine the antigen (Ag) specificity of the response. Following 
this first step of activation, the T cells require an additional co-stimulatory signal, to avoid 
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anergy or death by apoptosis. Co-stimulation materializes through assignation of T cell 
surface receptors with their associated ligands on APCs. Among the positive co-stimulatory 
molecules, is CD28 that is constitutively expressed on T cells, and that binds to either B7-1 
(CD80) or B7-2 (CD86) on APCs. Succeeding co-stimulation, T cells achieve complete 
activation, which encompasses cytokine production, clonal expansion and T cell survival 10. 
On the other hand, interaction of cytotoxic T lymphocyte antigen-4 (CTLA-4) expressed on T 
cells with APC-ligands B7-1 or B7-2, leads to a negative co-stimulatory signal, thus 
preserving tolerance and preventing immunological overshoot. 
 
FIGURE 2: TCR signaling involves several intracellular signaling pathways that activate transcription factors 
AP-1, NFkB and NFAT (Adapted from Schmidt A, Frontiers of Immunology, 2012). 
Inside the T cell, the cytoplasmic domains of CD3 proteins contain structures called immuno-
receptor tyrosine-based activation motifs (ITAMs). The TCR-complex is additionally 
associated with either CD4 or CD8 molecules (depending on the T cell subtype). These 
molecules have a cytoplasmic domain which upon activation will associate with cytoplasmic 
protein tyrosine kinases (PTKs) of the Src-family, such as Fyn and Lck, which further 
phosphorylates tyrosine residues on the ITAMs. This kick-starts the signaling cascade, and 
leads to the binding of signaling molecules to the phosphorylated ITAM domains.  The next 
step is facilitated by the binding of ζ–chain-associated protein kinase 70 (Zap70) to the 
phosphorylated ITAM tyrosine domains, that further activates three important downstream 
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intracellular signaling pathways. The end-product of this process is the induction of 
transcription factors such as NFAT (nuclear factor of activated cells), NFkB and AP-1. The 
combined action of these three transcription factor turn on the expression of genes required 
for T cell proliferation and differentiation, such as IL-2 11. 
3.1.4 Regulatory T cells  
The functional definition of a regulatory T cell (Treg) is a T cell that inhibits immunity by 
manipulating the activity of another cell type 1. Regulatory T cells play a central role in 
modulation of immune reactions to self-antigens, allergens and transplants, as well as 
immune responses to tumors and infectious microbes 12;13.  Both humans and mice deficient 
in or with dysfunctional Tregs, develop severe allergy, autoimmune and immune pathological 
diseases 14.  Regulatory T cells are also crucial in the maintenance of allograft tolerance and 
fetal-maternal tolerance during pregnancy 15. On the other hand, Tregs can also suppress 
antitumor immune responses and favor tumor progression. 
Regulatory T cells express the transcription factor forkhead box P3 (FoxP3) and are naturally 
present in the immune system. Most of FoxP3+ Treg cells are CD4+ T cells that express CD25 
(the IL-2 receptor a-chain), and can suppress the activation, proliferation and effector 
functions of a wide range of immune cells, such as CD4+ and CD8+ T cells, NK cells, B cells 
and antigen presenting cells. 
However, recent findings propose that Tregs are functionally and phenotypically diverse, 
with assorted suppressive mechanisms, identity and stability 16. Many cell subsets with 
regulatory activity have been described, including TGF-β producing Th3, IL-10 producing 
Tr1, CD4-CD8- T cells and CD8+CD28- T cells and NKT cells 17;18. These cells are 
peripherally induced Tregs (adaptive, aTregs), derived from naïve CD4+ T cells in the 
periphery 19-21, which means that they acquire regulatory functions following specific antigen 
stimulation in particular cytokine environments.  The aTregs develop during chronic antigen 
stimulation, and some but not all express Foxp3 22. PGE₂ exposure can induce Tregs by up-
regulating FoxP3+ expression in CD4+ CD25+ T cells and consequently enhancing their 
suppressive capacity 23. In addition, there are the TGF-β producing Th3 cells that are crucial 
in inducing and maintaining peripheral tolerance by driving the differentiation of Ag-specific 
Foxp3+ Tregs in the periphery 17. Tr1 is a CD4+ T regulatory type 1 cell that down-modulates 
immune responses through the production of the immunosuppressive cytokines IL-10 and 
TGF-β 18. Through IL-10 and TGF-β secretion Tr1 also facilitate CD4+CD25- T cell 
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conversion into CD4+CD25+FoxP3+ Tregs, while they require IL-2 for their peripheral 
maintenance 24. 
This is in contrast to the naturally occurring CD4+CD25+Foxp3+ regulatory T cell (nTreg), 
that our studies have focused on. These nTregs comprise a distinct T cell subpopulation that 
is developmentally determined in the thymus and is specialized for suppressive functions, 
rendering it critical in the maintenance of immunological self-tolerance and immune 
homeostasis 25. These nTregs account for up to 5-10% of peripheral CD4+ T cells 21, and are 
crucial to the fine balance between sustaining peripheral tolerance by suppressing potential 
autoimmune responses, while also controlling satisfactory responses to infections 20. 
 
FIGURE 3: Naturally occurring regulatory T cells suppress naïve and effector T lymphocytes. CD4+ T 
lymphocytes develop into adaptive Tregs during chronic antigen stimulation (adapted from Yaqub S, 2008). 
In Paper I of this Thesis we studied nTregs in peripheral blood from healthy donors to 
identify novel surface molecules to identify functional subsets.  
3.1.4.1 Treg characterization  
Regulatory T cells are CD4+ T cells characterized by their expression of the trans-membrane 
IL-2 receptor α chain (CD25) and the transcription factor forkhead/winged-helix family 
transcriptional repressor/activator p3 (Foxp3). Foxp3 controls the expression of many genes, 
and its forkhead (FKH) domain is critical for DNA binding and nuclear localization 26;27. 
FoxP3 is a transcriptional repressor for promoters of genes for the key cytokines IL-2 and 
granulocyte-macrophage colony-stimulating factor 3 (GM-CSF). Furthermore, FoxP3 
interacts with transcription factors that take important part in the expression of many cytokine 
genes, including nuclear factor of activated T cells (NFAT). Furthermore, ectopic FoxP3 
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expression induces suppressive activity in conventional T cells. And it is known that stop or 
frameshift mutations in the FoxP3 gene lead to Treg deficiency and a severe multi-organ 
autoimmune and inflammatory disorder, immunodysregulation polyendocrinopathy 
enteropathy X-linked syndrome (IPEX) 28. These findings suggest that FoxP3 is a master 
regulator of Treg cell differentiation and function. CD127 is another Treg “defining” 
molecule. Being the α-chain of the interleukin-7 receptor, CD127 expression correlates 
inversely with the FoxP3 expression and suppressive function of Tregs 24. However, 
conventional CD4+ T cells are known to down-regulate CD127 expression after activation, 
making CD127 negative status less useful to discriminate Tregs from activated T cells. 
 
In addition, several other molecules are expressed by Tregs, including the glucocorticoid-
induced tumor necrosis factor receptor-related protein (GITR), CD28/CTLA-4, CD95 (Fas), 
chemokine receptors, Toll-like receptors (TLRs), membrane bound TGF-β, 
CD45RO/CD45RA and other molecules, such as neuropilin-1, lymphocyte activation gene-3 
(LAG-3) and granzyme 19. None of these molecules are however uniquely expressed by Tregs 
alone, and there is still a race to find the best marker to characterize Tregs and differentiate 
them from activated T cells. 
The surface marker CD25 is an activation marker, and is expressed by all activated 
lymphocytes. Peripheral human blood contains up to 30% CD4+CD25+T cells, but only 1-2% 
of cells containing the highest CD25 expression have shown to be functionally suppressive. 
The transcription factor Foxp3 remains the most specific functional and phenotypic marker 
for Tregs, but being located in the nucleus it is difficult to access when trying to isolate or 
target viable Tregs for interventional purposes. Furthermore, Foxp3 is known to be induced 
in naïve CD4+FoxP3+ T cells upon stimulation, without conferring suppressive activity 29. 
These finding indicate that not all FoxP3+ T cells are inhibitory. 
Due to the heterogeneous nature of the function and phenotype of FoxP3+ T cells, Tregs have 
been divided into suppressive and non-suppressive subsets based on CD45RA and CD45RO 
expression. Naïve/resting Tregs that express CD25+CD45RA+FoxP3+ (rTregs) are in a 
quiescent state and have not experienced TCR stimulation-mediated maturation. These recent 
thymic emigrants are highly resistant to apoptosis, and they will proliferate, upregulate Foxp3 
expression and convert to CD45RA-FoxP3++ Tregs (aTregs) upon activation. The effector 
aTregs are an activated and functionally differentiated subset, known as CD45RA-FoxP3++. 
These effector aTregs are mainly derived from naïve rTregs and have potent suppressive 
capability. Following activation and suppression, these aTregs are highly susceptible to 
16 
 
apoptosis. The effector Tregs can be further subdivided based on their expression of ICOS 
and HLA-DR. While CD45RA-CD25+FoxP3++ ICOS+ effector Tregs produce the suppressive 
cytokine IL-10, the ICOS- cells actively secretes TGF-β. Furthermore, expression of HLA-
DR identifies an effector Treg subset that has a more profound ability to suppress T cell 
proliferation and to secrete cytokines when compared to HLA-DR-effector Tregs. HLA-DR+ 
Tregs are believed to represent a terminally differentiated subset in the effector Treg pool. 
Lastly, there is the non-Treg, CD45RA-FoxP3+ population that is non-suppressive and 
cytokine-secreting 30.   The difference between non-regulatory and functional FoxP3 Tregs 
may be linked to the methylation status of the Foxp3 gene, which is incompletely 
demethylated in CD45RA-FoxP3+ non-regulatory T cells but is completely demethylated in 
FoxP3+ Tregs with suppressive activity. This is partly helpful when assessing Treg function 
and when isolating cells. 
TABLE 1: Regulatory T cell subsets 
 
 
Previous attempts to find a unique Treg maker have been to no avail. Earlier studies have 
looked at the differences of DNA- and mRNA expression between CD4+CD25+Foxp3+ and 
CD4+CD25-Foxp3- T cells 31. However, many proteins undergo posttranslational 
modifications and not all mRNA is in fact further processed to proteins.  
No one has yet found a specific functional and phenotypic marker that truly sets the Treg 
population apart from the other CD4+ T cells in the human immune system, and Foxp3 
remains the most valid marker for Tregs. A possible way to discover a specific Treg 
biomarker might be with a proteomic approach, trying to find differences in molecules 
expressed on a protein level. That way one can target proteins specifically, in the nucleus, 
cytosol and membrane fraction, and this strategy was pursued in Paper I of this Thesis. 
3.1.4.2 Suppressive mechanisms 
Regulatory T cell suppressive activity requires prior activation of the Tregs through their αβ 
T cell receptor (TCR), but once activated they suppress in an antigen-nonspecific manner 22. 
The suppressive capacity of Tregs was for a long time considered to be dependent on a cell-
to-cell contact mechanism, leaving the concept of a soluble factor mediating Treg 
suppression controversial. However, although the precise molecular mechanisms of 
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suppression by human Tregs remains somewhat intangible, several studies report that Tregs 
employ several mechanisms to suppress and regulate an immune response, either by directly 
targeting T cells or antigen presenting cells. These mechanisms include inhibitory cytokines, 
cytolysis, metabolic disruption of target cells, and modulation of antigen presenting cell 
(APC) function (through decreased co-stimulation or decreased antigen presentation) 32;33. 
Numerous in vivo studies describe the importance of Treg-derived IL-10, PGE2, TGF-β, LAP, 
galectin-1 and IL-35 in the suppression of various immune responses 20;22;32;34. It has also 
been proposed that Tregs can directly suppress responder T cells through granzyme-A-
mediated cytolysis in a perforin-dependent, Fas-FasL-independent manner 35. Moreover, 
Tregs express CTLA-4 that binds tightly to the B7 molecules on APCs.  This binding 
decreases the APC co-stimulation and antigen presentation, thereby limiting the activation of 
effector T cells (Th1, Th2, and CTL) that is needed to mount an efficient immune response.  
Regulatory T cells can also suppress immunity by FoxP3 directly repressing the IL-2 gene 
transcription and consequently down-regulating T cell activation 29, or through IL-2 
consumption and cytokine deprivation. CD8+ Tregs suppress antigen-specific CD4+ T cells 
through a MHC I-independent way, through direct contact between Tregs and effector T cells. 
 
FIGURE 4: Regulatory T cells are induced in the tumor microenvironment and suppress anti-tumor immune 
responses. 
3.1.4.3 Tregs in cancer 
There is growing interest in and intense research on the role of Treg-based therapy. With 
regards to treatment of autoimmune disease and graft-versus-host disease, the transfer of 
expanded and pure Treg populations is under investigation. However, our main focus has 
been on Tregs in tumor immunology. Tumors can recruit Tregs to the tumor site, in addition 
to converting naïve and effector T cells into Tregs. Accumulating evidence indicates that 
Tregs are enriched in the blood, malignant effusions, draining lymph nodes and tumor tissues 
of various malignant diseases 36-38. Many studies have been conducted on Tregs and various 
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types of solid tumors. The presence of Tregs in colorectal cancer patients was increased in the 
vicinity of tumor invaded tissue, as compared to normal tissue 39. It has also been shown that 
the prevalence of CD4+CD25++ T cells inside the prostate was significantly higher in cancer 
tissue compared with benign tissue 40. Furthermore, studies have shown a strong correlation 
between the presence and amount of Tregs in gastric, hepatocellular, breast, colorectal cancer 
and melanomas, and poor clinical outcome and prognosis 38;41. Specifically, decreased ratios 
of CD8+ T cells to FoxP3+CD25+CD4+ Treg cells in tumors correlate with poor prognosis. 
The presence of elevated Treg numbers in cancer patients can prevent protective anti-tumor 
immunity, and recent clinical trials propose that reducing Tregs can be clinically beneficial 37. 
With the aim to target Tregs for immune potentiation purposes, efforts have been made to 
find cell surface molecules that are predominately expressed by Tregs or can specifically 
modulate Treg function. In mice there has been some success in augmenting tumor-specific 
immunity with the use of monoclonal antibodies targeting CD25 (a depleting antibody), 
CTLA-4 (a blocking antibody) and GITR (an agonistic antibody). In addition, small 
molecules such as cyclophosphamide can deplete Tregs and thus enhance anti-tumor 
immunity 42. CTLA-4-specific blocking antibodies are already in clinical use in treatment of 
advanced malignancies, such as malignant melanoma and non-small cell lung cancer 43-46. 
Since many Treg-specific cell surface markers are also expressed by activated effector T cells, 
there is an urgent need to find a specific Treg marker that sets the population apart from 
effector T cells. Another means of overcoming Treg induced anti-tumor immunity, is 
possibly through a combination of monoclonal antibodies that target different molecules to 
more efficiently control the balance between Tregs and effector T cells towards dominance of 
effector T cell immunity. 
3.2 Cancer immuno-editing 
The immune system has the potential to recognize and eliminate primary developing tumors, 
but it also has the capacity to promote tumor growth 3. The intricate relationship between 
developing tumors and the immune system was first described by Ehrlich in 1909 47, and later 
modified by Burnet and Thomas in 1957 48.  
Cancer immuno-editing is the process describing the immune system’s dual effect on 
developing tumors, and comprises elimination, equilibrium and escape 49. On the one hand, 
the abnormality of a malignant tumor should target it for immune destruction and elimination 
of the fast-growing cells. However, a tumor cell is also self. Protective mechanisms against 
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autoimmunity could therefore impede antitumor immunity and immune surveillance, 
allowing tumors to grow limitlessly. Sometimes the growth-and-attack interactions between 
enlarging tumors and the immune system cause no one to prevail, creating a state of 
equilibrium, or tolerance. Both the innate and adaptive immune system is implicated in 
antitumor responses, and in the dynamic interaction with the cancer leading to selection of 
escaping cells, termed immuno-editing 50. 
 
FIGURE 5: Cancer immuno-editing describes the intricate relationship between a developing tumor and the 
immune system, and comprises elimination, equilibrium and escape. This dynamic process gives rise to a 
selection pressure that leads to a survival benefit for clones with immune escaping properties. 
3.2.1 Tumor development 
Cancer develops as a result of an accumulating amount of altered genes that are involved in 
tissue homeostasis, cell survival and cell death. Mutated genes that facilitate tumor 
development can be classified into three types: oncogenes, tumor suppressor genes and DNA 
repair genes 51. Oncogenes stimulate cell growth under normal conditions, but mutations and 
“overexpression” in oncogenes cause continued cell growth in the absence of growth signals. 
Tumor suppressor genes act oppositely, and inhibit cell growth indirectly through promotion 
of programmed cell death (apoptosis), or directly by impeding the cells’ progression through 
the cell cycle. When tumor suppressor gene expression is lost as a result of mutations or 
allelic loss, the cells lose their normal inhibitory growth control. DNA repair genes control 
the rate of genetic mutation, and their mutation leads to a lack of repair, which consequently 
induces an accelerated rate of accumulated mutations in oncogenes (activation) and tumor 
suppressor genes (inactivation).  
However, a tumor doesn't merely consist of mutated cells, but constitutes a variety of 
components including fibroblasts, endothelial cells, extracellular matrix, cytokines, tumor 
infiltrating immune cells and tumor cells 52.  Together these constituents make up the tumor 
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microenvironment, and are all vital in the development, progression and treatment of cancer. 
Active interaction between all these components determines the phenotypic pattern of the 
tumor, its neovascularization and its ability to metastasize and invade surrounding tissues. 
The microenvironment is accordingly the focal combat zone during the neoplastic process 1. 
Cytokines and chemokines produced by the cells of the microenvironment are key mediators 
in this complicated interplay that is so crucial for tumor progression. 
3.2.2 Immune escape mechanisms  
Elimination and equilibrium of tumors is mediated by lymphocytes, and mainly the T cell 
subset. In several types of cancer, a high number of tumor-infiltrating CD8+  T cells is 
associated with improved clinical prognosis 36, as a full activation of adaptive immune cells 
in response to a tumor can eradicate malignant cells . In colorectal cancer the presence of T 
cells were more accurate in predicting patient outcome, than established prognostic factors 53. 
On the other hand, the abundant presence of innate immune cells such as macrophages and 
neutrophils correlates inversely with outcome, as their presence represents a chronic 
inflammatory environment. 
Unfortunately, the presence of tumor-specific CD8+ T cells rarely limits the tumor growth 1, 
as the tumors employ efficient means to avoid host immune attacks. One immune escape 
mechanism is through evasion of immune recognition, which can be achieved by selection of 
non-immunogenic tumor cell variants to avoid tumor antigen recognition. This is 
accomplished through several mechanisms, including down-regulation or loss of expression 
of major histocompatibility complex (MCH) class I molecules, and altered expression and 
functional activity of adhesive molecules and transport proteins 54. Furthermore, the 
expression of non-classical HLA-molecules (HLA-G and HLA-E) belonging to MHC class Ib 
inhibits NK cell-mediated cytotoxicity. In addition, defects in the maturation process of the 
antigen presenting dendritic cells can lead to tumor escape.  
The adaptive and innate immune cells create a selection pressure leading to the tumor cells 
surface changes, playing a significant role in “sculpting” the tumors immunogenicity. These 
changes also influence the sensitivity of tumor cells to the action of killer cells, making tumor 
cells harder to lysate and kill due to a change in surface ligands.  
Another immune escape method is by active suppression of the immune response. Persistent 
antigen stimulation is often evoked when tumors are unsuccessfully cleared by the immune 
system. When T cells are constantly exposed to antigens and hence activated, they over-
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express negative co-receptors, such as CTLA-4, Programmed Death I (PD1), FasL (CD95L) 
and B7-H4, leading to a down-regulated immune response 55-58.  
Another efficient tumor immune evasion mechanism is through the production of 
indoleamine 2,3 dioxygenase (IDO) by DC’s in tumors and tumor draining lymph nodes. 
IDO catalyzes the breakdown of the amino acid tryptophan into toxic metabolites, leading to 
T cell apoptosis and impaired T cell function 59. 
Chronic activation in the tumor vicinity also induces aTregs, while nTregs can traffic to 
cancer tissue, thus repressing anti-tumor immune responses. Myeloid suppressor cells are a 
subset of innate immune cells that accumulate in tumors and lymphoid organs, and can cause 
T cell dysfunction through direct cell-cell contact and production of immunosuppressant 
mediators 60. In addition, tumor cells themselves can suppress immunity directly through 
production of immunosuppressive molecules such as TGF-β, soluble Fas ligand, interleukin 
10 (IL-10), vascular endothelial growth factor (VEGF) and prostaglandin E 2 (PGE₂) 5;61-63. 
The combination of the aforementioned immune suppressive mechanisms that are employed 
by growing tumors, all contribute to tumor immune evasion, allowing malignant cells to grow 
limitlessly. This growing understanding of the complex interaction between developing 
tumors and the immune system is making way for novel therapies utilizing the potential of 
the body’s own defense mechanisms. 
3.3 Ovarian cancer 
The female ovaries are glands that contain germ cells (eggs), and ovarian tumors represent a 
range of distinct diseases that share this common anatomical location 64. Epithelial ovarian 
cancer (EOC) develops when a normal cell in the ovary transforms and grows uncontrollably. 
Approximately 85-90% of ovarian tumors originate from epithelial tissue covering the 
surface of ovaries, from the fallopian tube or the peritoneum (primary peritoneal carcinoma). 
The remaining 10-15% of ovarian tumors develops from germ cells, the egg-producing cells 
of the ovary, or stromal cells, the connective tissue cells that holds the ovary together and 
produces sex hormones. Epithelial ovarian cancer is acknowledged as a highly heterogeneous 
disease, and can be further subdivided into 4 main histological groups: Serous, mucinous, 
endometroid and clear cell tumors 65. EOC can also be separated into two broad categories; 
type I and type II. Type I tumors constitute 10-20% of all EOC and include low-grade serous, 
low-grade endometroid, clear cell and mucinous carcinomas. Type I tumors behave in an 
indolent way, by slow progression and restricted growth to one ovary. They are relatively 
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resistant to platinum, often constitute solid tumors and harbor p53 wild-type. Type II tumors 
on the other hand, represent 80-90% of all EOC and include high-grade serous, high-grade 
endometroid, mixed malignant mesodermal tumors (carcinosarcomas) and undifferentiated 
carcinomas 66. They grow more aggressively, respond to platinum, often harbor p53 and 
BRCA mutations, and are more genomic unstable than their counterparts. 
 
FIGURE 6: Ovarian cancer develops in the female ovarian glands. 
EOC is associated with high morbidity and mortality, and is considered among the most fatal 
malignancies in females 67. It is an exceedingly metastatic disease distinguished by 
widespread peritoneal dissemination and ascites. EOC will be the main focus in the ensuing 
sections. 
3.3.1 Epidemiology  
Every year, 250.000 women world-wide are diagnosed with ovarian cancer, making it the 6th 
most common malignancy and the 5th leading cause of malignancy related deaths among 
females globally. The estimated lifetime risk for a woman developing ovarian cancer is 1 in 
54, and this number is reported to be stable 68;69. Norway has a reported occurrence of 
approximately 450 new cases annually, with roughly 300 patients dying of the disease every 
year 70. The greatest incidence of EOC cases is found in postmenopausal women, in the age 
group between 40 and 65, with a mean age of 59 years 69;71. However, the mean age of EOC 
diagnosis is younger in women with hereditary ovarian cancer syndrome that have mutations 
in either the breast cancer type 1 (BRCA-1) or breast cancer type 2 (BRCA-2) gene, which 
affects up to 6% of Norwegian EOC cases. There is a steady increase of new EOC cases until 
the age of 80 years, when the rate flattens or drops 72. 
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The five year survival rate is generally poor, ranging from 30 to 92 %, depending on the 
spread of the disease at the time of diagnosis (Table 2). Common risk factors include early 
menarche and late menopause, age, obesity, nulligravidity, infertility, endometriosis, 
polycystic ovarian syndrome and family history 73. 
TABLE 2. Ovarian Carcinoma staging according to the International Federation of Gynecology and Obstetrics 
(FIGO). 
 
3.3.2 Ovarian cancer and immunity 
Accumulating clinical evidence supports the importance of immuno-editing mechanisms in 
EOC, both with regards to initiation and progression of the disease.  
EOC initiation is believed to be linked to chronic/subclinical inflammation in the 
reproductive tract, with immune constituents acting as mediators of epithelial transformation. 
The main hypothesis is that incessant ovulation, when ruptured ovulating follicles traumatize 
the ovarian surface during ovulation, causes an inflammatory response. This can further be 
linked to epidemiological evidence that shows a protective effect of multi-parity, oral 
contraceptive use and breastfeeding, which reduces the number of ovulations through a 
lifetime 74;75. The use of anti-inflammatory agents such as NSAIDs and aspirin has also been 
linked to reduced risk of epithelial carcinomas such as EOC, and will be more closely 
discussed in subsequent sections. In addition, inflammatory markers such as C-reactive 
protein (CRP) and interleukin-6 (IL-6) are associated with an elevated risk of EOC 76. IL-6 is 
produced by tumor cells, T cells and macrophages, and stimulates the JAK/STAT, PI3K/Akt 
and Ras/MEK/ERK pathway. The activation of these pathways is associated with ascites 
volume, tumor size and decreased survival 77. However, the role of IL-6 as a biomarker or 
part of an immune signature is more elusive. 
As EOC progresses, the effect of the immune systems become even more clear, and this has 
been attempted to be used in a diagnostic setting. Several cytokines are upregulated in the 
plasma and ascites of EOC patients, including IL-6, IL-8, IL-10, VEGF, etc 78. Attempts are 
being made to use these cytokines as biomarkers for early detection and pre-surgical 
diagnosis. 
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There is strong evidence that supports the association of antitumor immune responses and 
immune evasive mechanisms in EOC, with increased and reduced survival, respectively. For 
instance, ovarian tumors that are densely infiltrated with activated CD3+CD8+ cytotoxic T 
cells are strongly associated with a favorable clinical outcome regardless of stage and OC 
histology 79;80.These results suggest that host immunity and immune-surveillance plays an 
important part in EOC tumor development. Furthermore, the presence of CD3+CD4+Th17 
cells, a subset of CD4+ T helper cells, was also associated with improved survival. And the 
levels of Th17 cells were inversely correlated with Tregs, further emphasizing their potential 
importance in tumor eradication. On the other hand, the protective effect of NK cells and B 
cells present in EOC tumors, plasma and ascites, show mixed results regarding prognosis. 
And in contrast to the amplification of anticancer responses by effector T cells, Curiel et al. 
have shown that an increased number of CD4+CD25+FoxP3+ Tregs present in ascites fluid 
from EOC patients correlate with poor patient outcome 81. The same study also showed that 
Tregs were more abundant in malignant ascites, in contrast to non-malignant ascites and in 
peripheral blood. In addition, Sato et al. demonstrated that a low CD8+/Treg ratio decreased 
survival, while a high CD8+/Treg ratio was associated with increased survival in EOC 
patients 82. This suggests that the local tumor region is severely more immunosuppressed than 
the entire system, in part due to the presence of Tregs 83. Furthermore, EOC tumors 
contribute to an immunosuppressive environment through expression of negative cell 
regulators such as PD-1 and B7-H1, and IDO 84. 
The balance of effector and regulatory T cell is influenced by the developing tumor and the 
tumor microenvironment, as represented by surrounding ascites fluid. The progressively 
deficient immune response exhibited in the local EOC region and peritoneum, is partly 
responsible for the poor prognosis of EOC. It is evident that the tumor microenvironment 
affects the disease progression of EOC patients, making it a possible target for budding 
therapeutic strategies. New immune regulating strategies that augment the host immunity, 
while simultaneously preventing local immune-suppression, might thus be important to 
increase overall survival among EOC patients. 
3.3.3 Malignant ascites 
Ascites is a pathological accumulation of fluid within the peritoneal cavity that occurs when 
the body produces more fluid than it can remove from the abdomen. The term malignant 
ascites is frequently used when the fluid contains malignant cells and has a high level of 
lactate dehydrogenase 85. In healthy humans, the peritoneal cavity contains a certain volume 
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of lubricating peritoneal fluid. This fluid is needed to support organ mobility and to facilitate 
easy transfer of solutes between adjacent organs and the peritoneum. The precise amount of 
this peritoneal fluid is strictly regulated through secretion of small molecules from capillaries 
through the peritoneal membrane, and reabsorption through lymphatic channels. 
Excessive amounts of peritoneal fluid develop in EOC patients, when the tumor spreads to 
the abdominal cavity. The presence of tumor cells leads to disruption of the epithelial lining, 
increased leakiness of the tumor microvasculature, secretion from tumor cells and obstruction 
of lymphatic vessels. Tumor cells that have metastasized to the hepatic regions can also block 
blood flow through the liver, which pushes more fluid into the abdomen because of increased 
hydrostatic pressure. These processes can all contribute to the development of malignant 
ascites 86. 
In OC patients with advanced stage III to IV disease, the immediate tumor microenvironment 
is extended from the abdominal cavity in the presence of malignant ascites. Malignant ascites 
is a complex mixture of soluble components (cytokines, chemokines and growth factors) and 
a wide range of cell types (free floating tumor cells, immune cells, mesothelial cells, 
fibroblast and macrophages). The constituents of the malignant ascites together contribute to 
a tumor microenvironment that promotes inflammation and further drives tumor growth, 
angiogenesis and fosters tumor infiltration and metastasis, while concurrently impeding anti-
tumor immunity. We examined the immune-suppressive role of malignant ascites in Paper II. 
3.3.4 Diagnosis   
There are few, early clinical manifestations of EOC, and they are generally subtle and 
unspecific, like vague abdominal bloating, abdominal or pelvic pain, dyspepsia, urinary 
symptoms (frequency and urgency), difficulty eating or feeling full, flatulence etc. Other 
possible symptoms include fatigue, indigestion, constipation, pelvic masses, ascites fluid, 
menstrual irregularity, vaginal bleeding or back pain due to ovarian torsion, rupture or 
metastatic spread 72. However, most patients are asymptomatic. 
The most common physical finding is palpation of a mass during pelvic examination, which 
is the first line of diagnosis. But early stage tumors are difficult to find because of the deep 
anatomical location of the ovaries. Pelvic inspection is thus often followed by transvaginal 
ultrasonography (TVU), for a meticulous evaluation of the pelvic area. TVU can visualize the 
internal genitalia and detect solid masses and ascites. The challenge lies in distinguishing 
between normal physiological conditions, inflammation, benign tumors and ovarian cancer, 
26 
 
as the ultrasonographic findings rarely are pathognomic 87. Unfortunately, percutaneous 
biopsy is not recommended due to the risk of leaking tumor cells into the peritoneal cavity. 
Therefore TVU remains inadequate to diagnose EOC 73. Radiological evaluation with 
computed tomography (CT) and magnetic resonance imaging (MRI) can be used to 
demonstrate metastatic disease, but is not specific enough to be used in initial EOC diagnosis 
88. More recently, PET-CT has been introduced as a more thorough detection option for 
minor metastases, but it is not yet part of the standardized preoperative examination 89. 
Several hundred potential biomarkers expressed in EOC have been identified, but no single 
indicator has been found useful in diagnosis 90. Cancer antingen-125 (CA125) is a serum 
glycoprotein that is elevated in > 80% of patients with advanced EOC. However, it is neither 
specific, nor sensitive enough to be used as a screening tool or as a definitive diagnostic 
marker. CA125 is increased in other malignancies and benign conditions, and serum values 
fluctuate during the menstrual cycle 72. Nevertheless, it can be used to measure treatment 
success and detect disease relapse in patients with confirmed malignancies. Human 
epididymis protein 4 (HE4) is another protein that is often overexpressed in EOC, which has 
a sensitivity equal to CA125, but an increased specificity, as it is less frequently elevated in 
benign gynecological conditions 91;92. However, the level of HE4 fluctuates significantly with 
age, and it is commonly elevated in healthy elderly women 93. The use of CA125 and HE4 in 
combination is on the rise, and a treatment algorithm combining the two biomarkers to 
increase diagnostic accuracy was recently released, namely the “Risk of Ovarian Malignancy 
Algorithm” (ROME) score 94. 
Means of early detection are unfortunately very limited, and most patients present with 
metastatic disease when the cancer is discovered. The majority has reached FIGO-stage III-
IV (International Federation of Genecology and Obstetrics) at the time of diagnosis, with 
widespread carcinomatosis and accumulated malignant peritoneal fluid, ascites. In the end, 
only surgery is left as a diagnostic option.  
3.3.5 Treatment 
Surgery is typically performed to obtain representative tissue for diagnosis, disease staging, 
and for cytoreduction to remove as much cancer tissue as possible. Optimal surgical 
debulking improves patient outcome, and is usually followed by adjuvant chemotherapy 95. In 
cases where surgery is not possible, due to extensive disease or poor patient conditions, only 
chemotherapy is attempted.  
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Primary cytoreductive surgery includes hysterectomy, bilateral salpingoophorectomy, 
omentectomy and removal of iliac and para-aortic lymph nodes. The degree of cytoreduction 
has been shown to be the single most important independent prognostic factor for survival 
96;97, and centralized surgery has led to better outcomes due to improved competence, 
experience with advanced surgical procedures and the capability to better handle 
complications. 
Recommended chemotherapy regimens combine 6 cycles of paclitaxel- and platinum-type 
agents such as carboplatin, in the first-line treatment of EOC patients. And for subgroups 
with advanced disease or residual tumor following surgery, bevacizumab, a humanized 
antibody directed against VEGF, is also added to the regime 98-100. Paclitaxel and carboplatin 
are efficient in preventing tumor recurrence and improving survival. Paclitaxel works by 
binding to microtubules, preventing their de-polymerization, which then disrupts mitosis and 
pro-apoptotic signaling. Platinum-type agents such as carboplatin, are alkylating, and work 
through chemical cross-linking in DNA which interferes with DNA replication and 
transcription, thus leading to cell death. For patients with minimal gross disease remaining 
after surgery, and for patients that can also tolerate aggressive treatment, intraperitoneal drug 
administration is attempted, and it has significantly improved survival for many 72;101. 
However, its use remains limited, partly due to lack of tradition and increased complication 
rates 102. 
Second-line treatment is endeavored in patients with recurrent disease following initial 
complete response, and in those who did not respond adequately to initial treatment. Relapse 
rates have been reported up to 70% within 12-18 moths, with most cases being caused by 
drug resistance. Mechanisms facilitating drug-resistance include increased expression of anti-
apoptotic proteins Bcl-2 and XIAP, activation of Akt survival signaling and increased 
production of pro-inflammatory cytokines such as IL-6, IL-8, thus preventing paclitaxel from 
inducing apoptosis. Chemotherapy can be tried with a second course of the same regimen, 
alternatively a different regimen that comprises carboplatin with either gemcitabine or 
pegylated liposomal doxorubicin (PLD) may be used. Other options include bevacizumab for 
patients with platinum-resistant tumors (disease recurrence within 6 months), or secondary 
debulking surgery with an aim to remove recurrent disease or relieve symptoms for palliation 
103.  
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FIGURE 7: Treatment course for ovarian cancer. 
Ovarian cancer patients with advanced disease are initially highly responsive to surgery and 
platinum- and taxane-based chemotherapy, but the majority succumbs to recurrent disease 
that is resistant to further treatment 79. Despite efforts to cure ovarian cancer over the past 
decade, the advances in treatment has done little do reduce the overall survival rate, and 
established therapies fail to induce a cure at diagnosis 67.  Given the known limitation in 
current therapies and the association of endogenous immune responses with increased 
survival in EOC, research in targeted immune-therapy is of utmost importance. 
3.4 Colorectal cancer 
Colorectal cancer (CRC) is a term used to describe tumors that arise in the large intestines, in 
either the colon or rectum. About 98% of CRC cases are defined as adenocarcinomas, with 
tumors arising from glandular tissue that lines the inside of the intestines. Other rare types 
include squamous cell carcinomas, lymphomas and sarcomas. For the purpose of this Thesis, 
adenocarcinoma of the colon and rectum will be referred to as CRC. Tumors arising on the 
right side of the colon (cecum and ascending colon) tend to grow outward from the bowel 
wall, in an exophytic manner. These tumors rarely cause bowel obstruction, and the most 
common presenting symptom is anemia and abdominal discomfort. On the other hand, 
tumors of the left colon and rectum frequently grow circumferential, which may lead to 
bowel obstruction and thus ileus as a presenting symptom.  
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FIGURE 8. Colorectal tumors can develop in the right, transverse or left colon or in the rectum  
3.4.1 Epidemiology 
CRC is the fourth leading cause of cancer deaths worldwide, with about 3,5 million new 
cases and approximately 650.000 CRC-related deaths annually 104. Norway has about 3,500 
new cases yearly, and CRC constitutes about 15% of all diagnosed tumors nationally 105. 
CRC tumors are subject to staging to ensure appropriate method of treatment and for 
diagnostic and research purposes. The staging systems for CRC largely depend on the extent 
of local invasion, the degree of lymph node involvement and whether there are distant 
metastases. Currently, the TNM system (T: tumor invasion, N: lymphatic node, M: metastasis) 
is most commonly used. However, there is a need for a new staging system that takes into 
account recent advances in surgical techniques and the molecular and immunological profile 
of the tumor. 
The 5-year relative survival rate for CRC patients has improved over the last 30 years. 
Overall the 5-years survival rate is about 40%, but it varies from 13% if the disease presents 
with distant synchronous metastasis unavailable for surgical removal (stage IV), and up to 90% 
if the disease is localized at the time of diagnosis (stage I) 70. CRC tumors can spread by local 
growth, direct invasion of surrounding tissue (pelvic wall, ureters, vagina and uterus in 
women, and bladder), and also through lymphatic vessels and blood vessels. Up to 70-80 % 
of newly diagnosed CRC patients present with localized disease, but between 15-20 % of 
CRC patients present with hematogenous metastases at the time of diagnosis, also known as 
synchronous metastases 106. The majority of these metastases can be found in the liver, but 
CRC tumors also frequently spread to lungs and the peritoneum. About 35-45 % will develop 
metachronous liver metastases at a later stage 107. 
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3.4.2 Tumor biology 
The incidence of CRC is on the rise, and it is believed to be partly due to environmental and 
modifiable lifestyle factors. Known risk factors for developing CRC include age (> 60 years), 
diet (low intake of fiber and plant foods (fruits, vegetables, seeds, grains), high intake of red 
meat and saturated fat), gender (men are at higher risk for developing rectum cancer) obesity, 
physical inactivity, excessive alcohol consumption, tobacco, bowel inflammation etc 108-111. 
However, up to 70-85% of CRC cases occur without a known reason. On the other hand, 
about 20% of CRC cases are due to familiar factors, even though no known genetic 
disposition has been found.  
In addition to the sporadic and familiar cases of CRC, there are certain hereditary genetic 
conditions that predispose to CRC. The most prevalent ones are familial adenomatous 
polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC), also known as 
Lynch syndrome. FAP is caused by a mutation in the tumor suppressor and “gate-keeper” 
gene adenomatous polyposis coli (APC), which inhibits the oncogenic β-catenin signaling in 
the Wnt-pathway. Inactivation of the APC protein thus leads to uncontrolled growth of colon 
epithelium 112 and FAP is consequently characterized by colon polyposis. HNPCC is an 
autosomal dominant inherited disease characterized by mutations in DNA mismatch repair 
genes (MMR). These mutations prevent proper repair of DNA replication mistakes, thus 
leading to division of abnormal cells and uncontrolled cell growth.  
Most CRC tumors develop through malignant transformation of adenomas, even though only 
5-10% of existing adenomas develop into cancer 113. The aberrant crypts to adenoma to 
carcinoma sequence, is a multistep development from normal to dysplastic epithelium to 
carcinoma, which is caused by a multitude of genetic alteration. In addition to the previously 
mentioned mutations of DNA mismatch repair genes and inactivating mutations or allelic loss 
of the “gate-keeper” APC, CRC is often associated with activation of the oncogenes Kirsten 
rat sarcoma viral oncogene homolog (K-ras) and protein kinase B-Raf (BRAF), and 
inactivation of the tumor suppressor genes tumor protein 53 (Tp53), transforming growth 
factor-beta (TGF-β) and phosphatase and tensin homolog (PTEN). TGF-β is inactivated in 
about 1/3 of CRC tumors 114, while PTEN inactivation can be found in up to 20-30% of CRC 
cases. PTEN acts as a tumor suppressor, through counteraction of the PI3K-Akt-pathway, 
which in its hyper-activation state can promote malignant growth. Loss of PTEN action 
results in subsequent reduced apoptosis, stimulated cell growth and increased proliferation 115. 
The APC, K-ras and Tp53 mutations are associated with chromosomal instability (CIN), 
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which causes numerous changes in chromosomal copy number and structure 116. CIN is found 
in up to 70% of CRC tumors, making it the most common form of genomic instability in 
CRC 117. Microsatellite instability (MSI) is a “hypermutable phenotype” that occurs due to 
inactivation of DNA mismatch repair genes (MMR) 118. Microsatellites are tandem repeats of 
DNA that are particularly prone to errors during DNA replication, and MSI is found in up to 
15% of CRC cases, both sporadic and in hereditary HNPCC, which is caused by a mutated 
MMR 119.   Lastly, epigenetic silencing of gene expression, mostly mediated by aberrant 
DNA methylation, is a mechanism of gene inactivation through repressed transcription via 
the promoter region of tumor suppressor genes. CpG (-Cytosine-phosphate-Guanine-) island 
methylator phenotype (CIMP), refers to widespread hypermethylation of gene clusters termed 
CpG island loci, and is demonstrated in up to 15% of CRC’s 120.  Hypermethylation has also 
been associated with altered APC function and microsatellite instability. The serrated 
pathway describes CRC tumor development that is initiated by the presence of protein kinase 
B-Raf (BRAF) mutation and epigenetic silencing of genes involved in cell differentiation, 
DNA repair and cell-cycle control 121. 
 
FIGURE 9: Colorectal cancer pathogenesis (adapted from Mundade R, Oncoscience 2014, 1:6) 
Studies also show that APC and K-ras mutations regulate expression of cyclooxygenase-2 
(COX-2) through down-stream pathways, though the exact mechanisms remain intangible 122. 
A study emphasizing this showed that knockout of the COX-2 gene in mice resulted in 60% 
reduction of APC mutation induced intestinal adenoma 123, while other studies show that 
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APC can negatively regulate the expression of COX-2 124. In addition, the lipid kinase 
phosphatidylinositol 3-kinase (PI3K) is mutated in its catalytic subunit alpha polypeptide 
(PI3K-CA mutation) in up to 15-20% of CRC tumors. PI3K activates Akt, which through 
down-stream mechanisms work to regulate several signaling pathways important for 
carcinogenesis, such as cell proliferation, adhesion, survival and motility 125. Up-regulation of 
PI3K enhances COX-2 activity and PGE₂ synthesis, ensuing in reduced apoptosis in CRC 
cells 126. This will be elaborated in more detail in following sections.  
It is thought that all of the above pathways can overlap and this genetic diversity is crucial in 
understanding the tumor biology underlying CRC development.  
3.4.3 Cyklooxygenase and prostaglandin E₂ in CRC 
The cyclooxygenase (COX) isoenzymes are homodimeric glycosylated proteins located 
intracellularly on the luminal surface of the endoplasmatic reticulum and in the nuclear 
envelope. COX exists in 2 main isoforms; the constitutively expressed COX-1 is involved in 
the physiological production of prostaglandins, prostacyklins and thromboxane to maintain 
normal homeostasis. It is a housekeeping gene that is essential in the protection of gastric 
mucosa, platelet aggregation and to preserve the integrity/function of renal microvasculature. 
On the other hand, COX-2 is only constitutively present in brain, testis and renal parenchyma 
under regular circumstances, but is increasingly expressed in pro-inflammatory environment 
and neoplastic tissue, under the influence of mitogens, growth factors and cytokines such as 
lipopolysaccharide (LPS), IL-1, IL-2 and TNF-a 63. A third variant also exists, COX-3, which 
is a splice variant of COX-1127. COX-isoenzymes function as the rate-limiting step in the 
conversion of arachidonic acid, hydrolyzed from cell membrane phospholipids by a 
phospholipase A₂, to prostaglandin endoperioxide H₂ (PGH₂), the precursor of bioactive 
lipids such as prostaglandins (PGD₂, PGE₂, PGF₂ₐ and PGI₂) and thromboxane A2 (TXA2). 
Prostanoids normally act in a paracrine and autocrine manner to coordinate intercellular 
events stimulated by a circulating hormone 128. PGE₂ is considered the main player in CRC 
tumorgenesis, as a promotor of colonic adenoma development and progression 129.  PGE₂ 
activity is enhanced through increased COX-2 induction in a pro-inflammatory and tumor 
environment, and by the loss of 15-prostaglandin dehydrogenase (15-PGDH), the rate-
limiting enzyme in catalyzing degradation of prostaglandins 130.  
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FIGURE 10: COX-enzymes facilitate the conversion of arachidonic acid into bioactive lipids such as 
prostaglandins, thromboxanes and prostacyklin. This production can be inhibited by NSAIDs, aspirin and COX-
2-specific inhibitors. 
PGE₂ mediates its biological effect through binding to the prostanoid EP receptor family, 
which includes four subtypes, EP1-EP4 receptors, belonging to the G-protein coupled 
receptor family (GPCRs). The binding of PGE₂ to EP activates G-protein downstream 
signaling through increased intracellular levels of the second messengers cyclic adenosine 
3’,5’-monophosphate (cAMP) (EP2 and EP4) or phosphinositide (PI) signal transducers 
(EP3), which in the end induces a decline in adenylyl cyclase/cAMP. EP1 on the other hand, 
prompts calcium mobilization by activating phospholipase C, and amounts to a “contractile” 
receptor group. 
PGE₂ is an important facilitator of COX-2 associated effects, and its signaling through EP 
receptors promote tumor growth through a wide range of events, including promotion of 
proliferation, inhibition of apoptosis, stimulation of tumor invasion, angiogenesis and tumor 
immune evasion. This multitude of tumor promoting functions emphasizes the importance of 
COX-2-PGE₂ inhibition as a potential anti-tumor therapy. PGE₂ activates the Ras-MAP 
kinase cascade, a highly conserved intracellular pathway responsible for neoplastic cell 
proliferation in many human cancers. PGE₂ also trans-activates epidermal growth factor 
receptor (EGFR), which is upregulated in colon cancer and increases cell proliferation 
through activation of its down-stream mediator extracellular signal-regulated kinase (ERK).  
Furthermore, PGE₂ (through EP1) induces the expression of the intracellular anti-apoptotic 
mediator nuclear factor kappa B (NK-ᶄB), and directly inhibits programmed cell death 
through activation of both PI3-kinase and Wnt-signaling. In addition, COX-2 overexpression 
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is known to be related to elevated bcl-2 expression, resistance to pro-apoptotic stimuli and 
delays in G1 transit during cell cycle. Consequently, pharmacological inhibition of COX-2 
might inhibit tumor growth and increase apoptosis through these aforementioned pathways. 
Furthermore, the expression of EGFR on CRC cells also correlates directly with their ability 
to metastasize and invade surrounding tissue. Crosstalk between COX-2-PGE₂-PKB and 
EGFR-PI3K/Akt circuits stimulates cell migration and invasion to a further extent than EGFR 
alone, providing evidence that COX inhibition may reduce the spread of metastatic disease. 
COX-2 also induces the angiogenic factors vascular endothelilal growth factor (VEGF), basic 
fibroblast growth factor (bGFG), transforming growth factor (TGF-1), platelet-derived 
growth factor (PDGF) and endothelin, which are important for growth and survival of 
endothelial cells, stimulation of vascular endothelial cell migration and capillary 
formation131;132. Tumor cells need blood vessels to grow beyond 2-3 mm in dimension. PGE₂ 
is known to mediate the pro-angiogenic effects of COX-2, and several reports indicate that 
NSAIDs and aspirin have anti-angiogenic effects in CRC through these mechanisms 131;133. 
For instance, COX-2 inhibitors decrease VEGF production in fibroblast and tumor cells, and 
prevent VEGF-induced mitogen-activated protein (MAP) kinase (ERK2) activation in 
endothelial cells.  
Lastly, the Taskén group has showed that COX-2 and PGE₂ are known to induce tumor 
immune evasion in CRC by contributing to an immunosuppressive environment 39;134. For 
instance, CRC tumor cells can produce PGE₂ which directly inhibit the effector T cells 39. 
PGE₂ binds to EP2 and EP4 receptors on T cells which leads to increased intracellular cAMP 
and subsequent activation of the inhibitory pathway PKA – Csk – Lck, which leads to 
immunosuppression through inhibition of IL-2 production and proliferation135;136. PGE₂ also 
inhibits T cells through cAMP-independent pathways, through suppression of Fyn tyrosine 
kinase activity and adenylyl cyclase 137. In addition, PGE₂ induces FoxP3 expression and 
induction of adaptive Tregs138, which further inhibit the anti-tumor immune response. 
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Figure 11: Aspirin inhibits PGE2-induced tumor progression and angiogenesis, and reduces PGE2-mediated 
inhibition of anti-tumor immunity. 
COX-2 expression is elevated in nearly 50% of benign polyps and in about 80% of CRC 
adenocarcinomas. This overexpression is mostly due to abnormal regulation by transcription 
factors, mRNA stabilization and miRNAs, and not due to amplified gene copies. COX-1 
expression on the other hand, is usually found at normal or reduced levels as compared to 
normal mucosa. Furthermore, elevated levels of COX-2 expression have been associated with 
decreased survival in CRC patients, and it is also an independent risk factor for metastasis 
139;140. PGE₂ levels are known to be elevated in CRC patient blood samples when compared 
to healthy donors 39;141-143. PGE₂ levels are also found to be augmented in colonic adenomas 
and in carcinomas harbored by individuals with FAP and in sporadic CRC cases 141;144.   
3.4.4 Acetylsalisylic acid and CRC 
Acetylsalicylic acid, also known by its commonly used sales name, aspirin, is a non-steroidal 
anti-inflammatory agent (NSAID) and a ubiquitous drug, originally used as an analgesic and 
antipyretic medicine. Since 400 A.D., plants containing salicylic acid have been given to 
patients as a pain relief 145. Today it is among the most commonly used drugs world-wide, 
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with low toxicity and a well-known safety profile, while also being exceptionally low-cost. In 
addition to its known anti-inflammatory properties, aspirin is also widely used as a preventive 
drug against cardiovascular disease due to its platelet inhibitory action. In more recent years, 
occasional and regular use of aspirin has been associated with lower risk for gastrointestinal 
and other solid tumors, and its gaining use as a prophylactic cancer remedy. 
 
FIGURE 12: The chemical structure of acetylsalisylic acid. 
The biological plausibility behind the beneficial use of aspirin in CRC patients is thought to 
be through COX-1 and COX-2 inhibition. Aspirin and other NSAIDs work by inhibiting 
COX-induced transformation of arachidonic acid into prostanoids. On the on hand, aspirin 
inhibits COX-2 and the production of PGE₂. PGE₂ has several known anti-tumor effects, 
such as promotion of proliferation, survival, migration, invasion, angiogenesis and tumor 
immune evasion. Looking at the use of aspirin as a primary preventive drug against CRC, its 
key suppressive effects are only obvious after several years. This may indicate that the 
primary anti-tumor effect of aspirin is through inhibition of the adenoma to carcinoma 
sequence, by its known reduction of tumor growth and angiogenesis, whereas reversal of 
anti-tumor immune evasion would not come into play before the immune system has been 
exposed to an established tumor. Suppression of COX-1 on the other hand, may lead to 
reduced metastasis, through inhibition of platelets. 
37 
 
 
FIGURE 13: Several randomized controlled trials, case-control studies and cohort studies have been conducted 
to examine the correlation between aspirin use and colorectal cancer related outcomes.  
In 1968 it was reported that removal of platelets in rats impaired seeding of metastases, and 
later studies indicated that aspirin had a similar anti-metastatic effect in animal models 146;147. 
These results suggested that platelets play a part in the process of cancer metastasis, and that 
aspirin may suppress this course. Later, there were the slightly odd findings from 
cardiovascular trials that revealed that aspirin reduced non-vascular deaths compared with the 
placebo group. These results led to the hypothesis that aspirin may prevent cancer metastasis 
and incidence which was supported by a growing body of evidence. In parallel, a number of 
large placebo-controlled studies were conducted during the 1980’s, documenting the benefit 
of the aspirin inhibitory effect on platelet function and cardiovascular disease. Recently, these 
trials with aspirin versus control in prevention of vascular events were coupled to national 
cancer registries and revealed robust statistical effects on reduced cancer metastasis. Further 
studies were aggregated with longer follow-up time, suggesting that daily aspirin use also 
reduced cancer incidence and deaths 148-151.  These findings were particularly obvious in 
cancer of the ventricle, esophagus, breast, prostate, lung, and most importantly for CRC. In 
addition, several studies have been conducted in animal models and CRC-cell-lines, that 
show similar results, with reduced adenoma and tumor growth during NSAID treatment 123;152.  
Several randomized controlled trials followed, of aspirin, sulindac or COX-2 specific 
inhibitors (celecoxib and rofecoxib) as secondary prevention in patients with previous CRC 
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or polyps, or increased risk for these events due to hereditary disease 153-157. Many of these 
studies had recurrence of polyps as their chief outcome, and showed a reduction of recurrent 
polyps in patients receiving aspirin as compared to placebo 156;158. However, a slight draw-
back with looking at polyp recurrence is that it only acts as surrogate endpoint for CRC 
development. The trials using COX-2 inhibitors were stopped due to adverse cardiovascular 
effects 159. In sum, there exists a strong evidential foundation, both experimental and 
observational, suggesting that daily use of aspirin reduces cancer deaths, distant metastases 
and also reduces overall cancer incidence, establishing aspirin as primary preventive drug 
against CRC. 
Our chief interest was to study the effect of post-diagnostic aspirin use, to explore its use as 
an adjuvant remedy. Several studies have been conducted in this regard, looking at the effect 
of post-diagnostic aspirin use and overall and cancer specific survival in CRC patients. All 
studies, except one, show a benefit with aspirin use 160-166. But the recommended dosage and 
treatment duration remains unknown.  
TABLE 3: Summary of publications on aspirin use and survival after diagnosis of colorectal cancer. 
. 
Even though there is strong evidence in support of aspirin as a primary prophylactic agent 
against CRC, one cannot overlook the potential adverse effects of regular aspirin use over 
years, with increased risk of gastrointestinal and cerebral bleeding. It is possible to decrease 
the risk of gastrointestinal bleeding by concomitant use of proton pump inhibitors, but the 
risk of intracranial bleeding cannot be reduced. One must therefore carefully weigh the 
benefit against the risk of bleeding before recommending aspirin to healthy individuals that 
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have a low risk for developing CRC. This dilemma in particular, has led to a continuing 
debate on the use of aspirin in the healthy population and to the ongoing research on the use 
of aspirin as a potential secondary preventive measure to prolong survival in patients with 
established CRC tumors. We examined this effect in a Norwegian population with a registry-
based study (Paper III). 
In a secondary preventive setting, where the tumor is already established, the benefit of 
taking aspirin rapidly exceeds the potential harms, as the patients are at high risk of 
developing recurrent disease. As an adjuvant remedy, the most important protective effect of 
aspirin (in addition to the COX-1-mediated platelet inhibition) is believed to be facilitated 
through COX-2-PGE₂ suppression of anti-tumor immune response. PGE₂ is secreted by 
several important players in the tumor microenvironment, such as regulatory T cells, 
dendritic cells and tumor cells, and this PGE₂ suppresses the anti-tumor effector T cells 
directly, as described previously. 
3.4.5 Diagnosis  
Patients that seek medical advice for symptoms associated with CRC are initially subject to a 
case history recording. Common presenting symptoms include anemia, bloody stools, weight 
loss, night sweat, loss of energy and diffuse abdominal symptoms. However, some patients 
also present with acute symptoms due to intestinal perforation as a result of obstructive ileus. 
The case history is followed by a clinical examination which consists of an abdominal and 
rectal palpation to assess for masses. Rectal exploration can recognize up to 70% of all rectal 
tumors and 30% of colon tumors, and often includes a Fecal Occult Blood Testing (FOBT). 
FOBT is a simple, cheap and noninvasive diagnostic test which indirectly checks for 
gastrointestinal bleeding through enzymatic or immunological assessment of hemoglobin in 
feces. An important limitation for FOBT is its low sensitivity at detecting early-stage lesions, 
and its low specificity as ingestion of certain foods (red meats, fruits, vegetables) and 
medicines (non-steroidal anti-inflammatory drug) lead to false positive results 167. Future 
stool-based biomarker analysis will most likely be based on analysis of DNA for known 
mutations such as APC, K-Ras and p53, epigenetic markers such as MSI and/or by measuring 
unfragmented long-form DNA (L-DNA). Recently a large population-based study revealed 
that a fecal DNA panel consisting of 21 mutations detects a greater proportion of CRC than 
FOBT without compromising specificity 168;169.  Other commonly used cancer biomarkers 
include serum detection of carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-
9). CEA is commonly elevated in CRC; however it is not eligible for screening purposes, due 
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to insufficient sensitivity and specificity, but it can be used to monitor disease progression. 
CEA levels often decrease post-operatively, and increase during relapse. In addition, 
increased CEA levels correlate with poor disease outcome. Other proposed tumor markers 
includes cancer antigen 19-9 (CA 19-9), which is the second most investigated 
gastrointestinal tumor marker. Unfortunately, CA 19-9 has an inferior sensitivity to CEA, and 
is thus less commonly applied for diagnostic purposes.  
If the notion of CRC is strengthened through clinical examination and/or biomarker testing, 
the next diagnostic step for confirmation of disease is through examination with an 
endoscope; sigmoidoscopy and/or colonoscopy. Endoscopic examination allows for 
localization and biopsy of suspected lesions, and has a sensitivity and specificity for tumor 
and polyp recognition of 92-97%. However, endoscopy is an interventional method with 
known side effect such as patient discomfort, bleeding and intestinal perforation. Recently, 
non-invasive procedures have been introduced, such as noninvasive virtual colonoscopy 
which allows for 3D visualization of the large intestine. However, these non-interventional 
procedures do not allow for biopsies which are often needed to confirm the presence of 
malignant cells. FOBT and flexible sigmoidscopy is also recommended as a feasible 
screening option for CRC, but will not be more closely discussed in this Thesis 170. If a 
malignant tumor is confirmed, further pre-operative examination with ultrasonography, CT or 
MRI is conducted to look for metastatic disease.  
3.4.6 Treatment 
Depending on the established tumor stage, the recommended treatment regimens differs. In 
low-risk carcinomas, local procedures such as endoscopic mucosal resection or a 
laparoscopic segment resection are often sufficient enough. Early-stage tumors are commonly 
treated with radical hemicolectomy with lymph node resection (curative (R0) surgical 
resection) and no additional treatment. On the other hand, tumors that invade the serosa or 
have spread to local lymph nodes have a higher risk of recurrence, and should thus be treated 
with adjuvant remedies in addition. Rectum cancer patients often receive several rounds of 
radiation therapy, which has led to significant increase in survival over the last years. In 
patients presenting with tumor load exceeding surgical options, neo-adjuvant chemotherapy 
is attempted for tumor down staging 171, followed by surgery if successful. 
Adjuvant chemotherapy is consistently offered to patients with stage III disease, and it is 
considered in some instances to stage II patients (tumor perforation during surgery or less 
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than 8 lymph nodes examined in the resected tissue). First line chemotherapy consists of 
fluoruracil (5-FU) and calsiumfolinate/leucovorin (folinic acid administered as calcium) in 
combination with oxaliplatin. 5-FU is an antimetabolite which irreversibly inhibits 
thymidylate synthase (TS), required for the conversion of deoxyuridine monophosphate 
(dUMP) into thymidine monophosphate (dTMP). 5-FU causes a scarcity in dTMP, leading to 
cell death in rapidly dividing malignant cells. Calsiumfolinate is an adjuvant which works 
synergistically with 5-FU, as it stabilizes the 5-FU-TS complex, thus enhancing the toxicity 
of 5-FU 172. Oxalaplatin is a platinum-type alkylating agent which interferes with DNA 
replication and transcription through chemical cross-linking in DNA, causing cell death 173. 
This combination regime is known as the FLOX-protocol, and is considered the gold standard 
of care in the adjuvant setting, having led to significantly improved survival for CRC patients. 
Patients between 70 and 75 years are only given 5-FU and calsiumfolinate (FLV-protocol), 
and in older patients the need and tolerance for chemotherapy is considered individually. 
Another option is the FLIRI-protocol, where FLV is administered with irinotecan, a 
topoisomerase inhibitor which prevents DNA from unwinding174. 
In patients that present with concomitant metastatic disease or poor performance status, an 
addition of a biological agent that enhances the effect of cytotoxic therapy is considered. 
These include bevacizumab, an angiogenesis inhibitory antibody that targets VEGF, which 
may be added to the first line therapy regimen in patients expected to tolerate this therapy. 
Other options include the addition of cetuximab/panitumab, an antibody targeting EGFR-
receptors, and which shows an enhanced benefit in patients harbouring K-Ras wild-type 
tumors 174. 
Patients with locally advanced rectum tumors (10-15% of cases) that present with short 
margins to the surgical dissection plane are subject to a combination of neoadjuvant chemo- 
and radiation therapy. The concomitant radiation-sensitizing chemotherapy consist of one of 
two possibilities: oral capecitabine which is a prodrug that is enzymatically converted to 5-
FU, or Nordic FLV which is administered intravenously. 
A leap in surgical technology has pushed the boundaries of what is rendered possible with 
regards to cytoreductive primary surgery and resection of metastatic disease. Several case 
series have shown that patients with liver metastasis can achieve long-term survival when 
liver metastases are resected 175, and it is recommended to attempt curative resection of CRC 
liver metastases (CRLM). These liver-directed therapies in metastatic colorectal cancer 
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includes hepatic resection/hepatectomy, systemtic chemotherapy, portal vein embolization 
(PVE), two-stage hepatectomy, hepatic artery infusion, radiofrequency ablation (RFA), 
microwave ablation (MWA) and cryoablation. A recent review reported that 15-30% of 
CRLM patients may be eligible for curative resection, which results in an improved 5-years 
survival between 30 and 60% 176. We have analyzed the results of ten years of CRC 
resections in Oslo (Paper IV).  
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4 Aims of the study 
 
The aims of this Thesis were to explore tumor immune modulating properties at an 
experimental level, and CRC treatment options at an observational level. 
A limitation in the study of Tregs is the lack of a distinct Treg biomarker that sets the 
population apart from other T cells. FoxP3 is a lineage-specific transcription factor that 
directs many of the distinct properties of the Treg subsets. However, in humans, FoxP3 is not 
uniquely expressed in Tregs alone, and its presence in the nucleus makes FoxP3 unavailable 
for isolation and measurements of live Tregs.   
Secondly, we wanted to look at OC patients for our investigation of anti-tumor immunity. 
Previous studies have been made where the presence of Tregs was shown to correlate with 
poor patient outcome regardless of FIGO staging, and a parallel study was conducted in our 
lab to assess the function of ascites-derived T cells and Tregs 2. Here, we also wanted to 
investigate immune modulating properties of soluble factors in the tumor vicinity, using cell-
free components of ascites (Paper II). Ascites fluid produced by OC constitutes a valuable 
compartment for the exploration of the tumor microenvironment, as tumor cells, immune 
cells and proteins are freely suspended in the fluid. 
In addition to exploring the immune modulatory properties of tumors at a molecular level, we 
wanted to expand our view of new treatment options for CRC patients. We studied CRC 
patients in general with regards to post-diagnostic aspirin use. Aspirin is a NSAID that 
inhibits tumor development through several mechanisms, including modulation of anti-tumor 
immune responses, and its use is associated with reduced CRC incidence, mortality and 
metastasis. Our main focus was to explore the use of aspirin as a possible post-diagnosis 
remedy (Paper III). Patients with CRC that present with metastases have decreased survival 
rates, but recent attempts to treat liver metastases with more aggressive surgical procedures 
have led to improvements. We have examined results of surgical practice in CRC patients 
with liver metastasis over a ten years period (Paper IV). 
The work in this Thesis attended to some of the issues raised. Specifically our aims were to: 
I. Search for and characterize a specific Treg biomarker and if possible establish and 
test new methods for Treg isolation based on their expression of distinct surface 
markers (Paper I). 
II. Investigate the immune suppressive properties of the OC tumor microenvironment, 
as represented by cell-free ascites fluid. 
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III. Examine the effect of post-diagnostic aspirin use on survival in CRC patients, in a 
retrospective registry-coupled cohort study. 
IV. Study the impact of new surgical treatment strategies applied to CRLM patients 
on improved survival. 
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5 Synopsis of publications included 
Paper I 
CD147 (Basigin/Emmprin) identifies FoxP3+ CD45RO+CTLA4+-activated human 
regulatory T cells.  
In this paper we examined CD147 as a potential novel Treg biomarker. A proteomic 
approach was used to yield a list of proteins with a preferential expression on 
CD4+CD25 (Tregs) vs. CD4+CD25- (effector T cells). 28 proteins in total appeared to be 
uniquely expressed on Tregs, including Foxp3, and out of these, 11 were located in the 
membrane compartment. 4 of the 11 membrane proteins solely expressed on Tregs, CD147 
(Basigin/Emmprin), CD148 (receptor-type tyrosine-protein phophatase-eta), CD71 
(transferrin receptor protein 1) and CD95 (tumor necrosis factor receptor superfamily 
member 6), were also known to have extracellular domains. We further characterized these 
by flow cytometry (Fcm) analysis and showed that their expression correlated with CD25+. 
CD147 displayed the strongest correlation with CD25 expression, with 59.7% of CD25+ T 
cells staining positive for CD147. 
 
CD147 divided CD4+CD25+ T cells in two clear subpopulations and was thus chosen for 
further analysis. The CD147 and Treg correlation was additionally confirmed when the 
CD4+CD25+CD147+ subset expressed significantly higher levels of Foxp3 than the 
CD4+CD25+CD147-cells. Increasing CD147 expression correlated with rising levels of the 
Treg markers CD25, GITR, ICOS, CTLA-4 and CD38. CD147- also correlated with the 
naïve Treg marker CD45RA, while CD147+ and CD147++ were CD45RO+. These results 
indicate that CD147 represents an activated Treg subset. 
 
CD147 expression corresponded with the CD4+ CD25+CD127- T cells, demonstrating that 
CD147 identifies a distinct Treg subpopulation. Additionally, isolation of 
Tregs based on CD147+CD127- yielded a higher amount of FoxP3+ cells, as compared to the 
established method based on CD25+CD127low expression, thus ascertaining CD147 as a novel 
marker for Treg isolation. 
In CD25 enriched populations, CD147+CD25+ or CD147+Foxp3+ cell numbers were 
independent of T cell activation. In the CD25 depleted population the double positive cell 
populations increased significantly upon T cell activation. After stimulation the CD25-
CD147-cells expressed high levels of CD25 and CD147, thus obtaining a CD25+CD147+ 
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phenotype, and providing a source for CD147+FoxP3+ cells. The functional difference 
between CD147+ and CD147- Tregs became apparent through their different suppressive 
mechanisms. CD147+CD25++ Tregs significantly inhibited T cell proliferation more 
efficiently than CD147-CD25++ Tregs, against both CD4+CD25-CD147+/- T cells. 
The cytokine production also differed between CD4+ FoxP3+ T cells based on their CD147 
expression. CD4+FoxP3+ and CD4+FoxP3- populations were split in three subsets based on 
their CD147 expression (CD147-, CD147+ and CD147++) to study their cytokine producing 
potential. Irrespective of FoxP3 expression, CD147+ cells produced the most IL-2, IFN-γ, 
TNF-α and IL-17, while CD147++ showed a limited ability to produce any of the cytokines 
tested. Lastly, CD147 expression directly related to T cell subsets as defined by CD45RA and 
FoxP3. Naïve Tregs are CD45RA+FoxP3+ and express low levels of CD147. Highly 
suppressive and activated Tregs are CD45RA-FoxP3+ and express high amounts of CD147 
(CD147++), while the cytokine-producing non-suppressive population is CD45RA-FoxP3+ 
and express moderate amounts of CD147 (CD147+). 
These findings establish CD147 as a direct marker for activated Tregs within the 
CD4+FoxP3+ subset, providing potentially important means to manipulate Tregs in immune 
regulation. 
Paper II 
Characterization of immunosuppressive properties of malignant ascites in ovarian 
carcinoma 
The main objective of this study was to explore contact-independent immune suppressive 
mechanisms by humoral factors in malignant ascites from ovarian carcinoma that target 
effector T cells 
We assessed the effect of cell-free ascites on autologous T cell function and showed that it 
was suppressive in a dose-dependent manner. These findings were further confirmed when 
ascites supernatant also inhibited allogeneic T cell proliferation. Ovarian cancer cells that 
were isolated from malignant ascites were further cultured and the produced supernatant was 
subsequently incubated with PBMC without demonstrating any suppressive ability. This 
indicated that the suppressive factor in ascites is probably not produced by ovarian tumor 
cells. As a control we also cultured cells from the OC cell-line SKOV-3 in a similar manner, 
and the culture mediums from these cells were again not able to suppress allogeneic T cell 
proliferation. 
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In a further attempt to evaluate the suppressive properties of malignant ascites supernatant, 
we co-cultured allogeneic T cells and ascites in the presence of different inhibitors aimed at 
immune-modulating molecules, some which are known to be elevated in malignant ascites 
from OC patients, including IL-6, PGE2, IL-10, IL-8, CTLA-4, PD-1, B7-DC, B7-
H1c(blocking antibodies), PI3K-delta (inhibitor). Among these factors, only the presence of 
anti-PGE2 did to some extent increase the proliferation, though not significantly. Through a 
more biochemical approach, we subjected cell-free ascites from ovarian cancer patients to 
different pre-treatments such as heating, acetone precipitation and proteolysis. We found the 
inhibitory factor(s) to be sensitive to proteases and denatured by heat and acetone. 
 
In sum, we revealed that ascites supernatant displays global inhibitory activity against 
allogeneic and autologous T cells, and that this suppression is alleviated by heat and 
proteolytic treatment. In addition, we showed that this suppressive factor is neither secreted 
by ovarian cancer cells themselves, nor to be found in acetone precipitate. Lastly, we found 
that the inhibitory activity is most likely not caused by the sole functions of neither IL-6, 
PGE2, IL-10, IL-8, CTLA-4, PD-1, B7-DC, B7-H1 nor PI3K. 
Paper III 
Impact of Aspirin as Secondary Prevention in an Unselected Cohort of 25,644 Patients 
with Colorectal Cancer – A Population-Based Study 
Regular use of aspirin (acetylsalicylic acid) has been associated with reduced incidence and 
mortality of colorectal cancer (CRC). However, the use of aspirin as primary prevention in 
the general population is still being debated due to the risk of serious hemorrhagic side 
effects. In contrast, the use of aspirin as secondary prevention in patients with CRC may be 
more justified from a risk-benefit prospective. This study was conducted to examine the 
association between aspirin use after diagnosis of CRC with CRC-specific survival (CSS) and 
overall survival (OS) in the largest cohort examined to date. 
An observational, population-based, retrospective cohort study was undertaken by linking 
patients diagnosed with CRC from 2004 through 2011 (Cancer Registry of Norway) with the 
use of aspirin in the same patients (The Norwegian Prescription Database). The registries 
used cover more than 99% of the Norwegian population, and include all cases in an 
unselected manner. Exposure was defined as having received prescription for more than 6 
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months of aspirin after diagnosis of CRC. Multivariate Cox proportional hazard analyses 
were used to model survival. The main outcome measures of the study were CSS and OS.  
In total, 25,644 patients fulfilled our inclusion criteria in the study period and 6,119 of them 
were defined as exposed to aspirin after the diagnosis of CRC. The median follow-up was 3.0 
years. Among aspirin exposed cases (n = 6,119), a total of 2,088 (34.1%) deaths were 
recorded of which 1,172 (19.2%) were CRC-specific. Among non-exposed aspirin cases (n = 
19,525), a total of 9,683 (49.6%) deaths were recorded of which 7,528 (38.6%) were CRC-
specific. In multivariate analysis, aspirin exposure after the diagnosis of CRC was 
independently associated with improved CCS (hazard ratio [HR], 0.84; 95% confidence 
interval [CI], 0.78-0.90) and OS (HR, 0.94; 95% CI, 0.89-1.00).  
Adjustments were made for age, gender, differentiation grade, disease stage, tumor 
localization, surgery, and the use of possible confounding drugs such as metformin, beta 
blockers, ACE-inhibitors, statins and NSAIDS/coxibs. In sum, our results indicate that 
exposure to aspirin after the diagnosis of CRC is independently associated with improved 
CSS and OS.  
Paper IV 
Aggressive treatment of patients with metastatic colorectal cancer increases survival: a 
scandinavian single-center experience. 
We examined overall and disease-free survival in 239 patients in this study cohort of patients 
with metastatic colorectal cancer. Stratification of the data was carried out according to 
whether the patients received neoadjuvant chemotherapy, the number of resections and the 
surgical technique applied. In this report we show that patients that had a high tumor load and 
were initially rendered inoperable, were able to achieve a life expectancy and oncologic 
outcome similar to patients that were primary resectable, after having received neoadjuvant 
chemotherapy for tumor downstaging. Furthermore, we were able to show that disease 
recurrences develop with a similar time interval after the primary tumor and subsequent 
metastases (11±1 months), and that the overall and disease-free survival is comparable after 
every resection. These results substantiate recent findings in the biology of tumor 
development and metastases, and suggest that disease relapse may in fact represent an 
equivalent progress of metastases that reach a detectable state at different time points, as 
opposed to a continuing tumour development that rapidly acquires augmented malignant 
potential. In accordance with these findings, we also observed that later recurrences 
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represented a shift in target organs, without substantially changing clinical outcome. In 
addition, we report that neither the presence of positive resection margins nor the presence of 
resectable extrahepatic disease at the time of the first liver resection, has an inverse 
correlation with overall survival. These results are in line with emerging evidence in support 
of a novel classification system in metastatic CRC. Metastatic CRC has an unfortunate 
forecast, but it is becoming increasingly evident that surgical treatment has obvious patient 
benefits, and strategies to make patients resectable and accessible for surgery should be 
pursued. 
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6 Discussion 
 
Despite substantial development in the field of cancer research in recent years, the prognosis 
of patients with solid tumors with metastases remains nearly unchanged. In addition we are 
experiencing a rise in cancer incidences worldwide, particularly with colorectal cancer. The 
development of tumor immunotherapy as a therapeutic strategy has undoubtedly provided 
promising results in recent years. However, to excel at prevention, early detection and 
treatment of malignancies, it is of utmost importance to understand the development of tumor 
formation, its progression into systemic disease and interaction with host immunity. An 
introduction to the field has been presented in previous sections. In the following, our results 
will be discussed with emphasis on how future patients may benefit from findings presented 
in the included papers. 
6.1 Defining a regulatory T cell (Treg) subset 
The importance of regulatory T cells in a vast number of diseases, ranging from autoimmune 
disease and allergy to tumors, has been established in a large number of publications during 
the last 20 years. However, to target Tregs for therapeutic purposes, either to enhance or 
diminish their activity, has proved difficult due to the lack of a specific, Treg-defining surface 
marker. Another obstacle is the heterogeneity and stability of the Treg population, as they 
have proven to be a rather functionally and phenotypically diverse subset. 
In Paper I of this Thesis, we set out to find a surface marker that distinguishes the Treg 
population from activated CD4+ T cells, through a proteomic approach (combination of 
subcellular fractionation, proteomics and flow cytometry). This enabled us to identify a set of 
membrane proteins with extracellular domains that were highly expressed on the cell surface 
of Tregs as compared to activated T cells. Among these, the most interesting one was the 
immunoglobulin superfamily member CD147, or extracellular matrix metalloproteinase 
inducer (Emmprin) or Basigin.  
CD147 has previously been shown to be expressed by activated CD4+ T lymphocytes in the 
periphery, and to correlate with increasing amounts of CD25 and HLA-DR 177. CD25 (IL-2 
receptor) is a well-known activation marker for T cells, while HLA-DR has been proposed as 
a marker for an effector Treg subset with an increased suppressive capability. Furthermore, 
HLA-DR Tregs may represent a terminally differentiated subset in the activated Treg pool. 
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This is in line with our findings, as we show that CD147 can be used to identify human 
FoxP3 Tregs with an activated phenotype. 
Miyara et al. 30 were among the first to functionally divide the Foxp3 Treg compartment into 
three subgroups; resting Tregs (rTregs), activated Tregs (aTregs) and cytokine-secreting non-
suppressive FoxP3+ cells (cytokine-secreting FoxP3+). Phenotypically, these cells can be 
distinguished based on their expression of the naïve T cell marker CD45RA and FoxP3 as 
CD45RA+FoxP3+ rTregs, CD45RA-FoxP3++  aTregs and CD45RA-FoxP3+ cytokine-
secreting FoxP3+  cells. CD45RA-FoxP3+ cytokine-secreting FoxP3 cells are non-suppressive, 
and are believed to belong to the Th17 family due to their expression of transcription factor 
retinoid acid receptor(RAR)-related orphan receptor C (ROR-C), and their secretion of IL-17, 
IL-2 and TNF-a. Both rTregs and aTregs exhibit a suppressive phenotype, and upon 
activation the rTregs are able to proliferate and convert to aTregs. In Paper I of this Thesis, 
we demonstrate that CD147 may mark the switch from a naïve to an activated state, and thus 
contribute to the identification of an activated and highly suppressive CD45RO+ Treg subset. 
We show that CD147 splits the FoxP3 population and categorizes the aforementioned 
CD45RO+ subsets; aTregs correspond to CD147++, rTregs with low expression of CD147-, 
and the non-suppressive FoxP3+ T cell is equivalent to the cytokine-producing non-
suppressive CD147+ subset. Although these three subsets expressed different amounts of 
FoxP3 protein, exhibited distinctive cytokine-producing potential and suppressive ability, 
they expressed comparable amounts of FoxP3 transcripts. This substantiates the significance 
of defining and delineating Tregs subset dissimilarities at the protein level and the necessity 
to better describe their functions. Our results demonstrate by direct comparison that the level 
of CD147 staining directly aligns with the CD45RA/FoxP3 defined subsets and that the level 
of CD147 expression (CD147-, CD147+, CD147++) correlates with the activation status and 
function of human FoxP3 cells.  
A complicating matter in the research on human Tregs, is the functional heterogeneity 
between different FoxP3+ subsets and more dynamic expression of FoxP3 itself.  It has 
previously been shown that the difference between non-regulatory and functional FoxP3 
Tregs may be linked to the methylation status of the Foxp3 gene, which is incompletely 
demethylated in the non-suppressive cytokine producing CD45RA-FoxP3+ non-regulatory T 
cells, but is completely demethylated in FoxP3+  Tregs with suppressive activity (aTregs and 
rTregs). In line with this, we demonstrated that the Treg-specific demethylated regions 
(TSDR) of the FoxP3 gene were > 90% demethylated in CD147++CD25++ activated Tregs 
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(aTregs), CD147++CD25- activated effector T cells and CD147-CD25++ resting Tregs (rTregs). 
In contrast, the TSDR in CD147+CD25- naïve T cells were about 75% methylated. This 
epigenetic status marker indicates stable expression of FoxP3 in the CD147++CD25++ 
activated Treg lineage, and is partly helpful when assessing Treg function and when isolating 
cells. 
Tregs employ a number of mechanisms to exercise their suppressive functions, including IL-
2 consumption, secretion of suppressive cytokines and cell-to-cell contact-dependent 
mechanisms. CTLA-4 is a known negative co-stimulatory T cell molecule that is upregulated 
on activated T cells and on Tregs. CTLA-4 is also described to play a key role in regulating 
Treg suppressive activity, and high CTLA-4 expression correlates with activated, highly 
suppressive human Tregs. In Paper I of this Thesis, we show that there is a strong positive 
association between accumulative CD147 expression and CTLA-4 within the FoxP3+ Treg 
subset. We also show that CD147 expression correlates with ICOS, which has also been 
proposed as a Treg marker. In addition, we were able to show that the CD147 expression 
correlated with the suppressive function of Tregs, using a CFSE assay, which is the preferred 
assay for Treg-inhibiton-assessment.  These findings further support that CD147 can be a 
useful marker to target and study functional subsets of human Tregs. 
 
Our Treg work revealed CD147 as a potential novel biomarker for activated Tregs. Surface 
markers that allow identification of phenotypically and functionally homogeneous Tregs 
subsets are crucial, both for functional analysis and therapeutic approaches. As mentioned 
previously, FoxP3 remains the most renowned Treg marker due to its distinctive expression 
in Tregs. However, both targeting of Tregs for interventional purposes and purification of 
Tregs for functional assays must be based on surface markers, rendering FoxP3 an 
impractical option. A common approach, also partly used in our study, has been through a 
combination of positive selection using CD25 and negative selection using CD127. However, 
this approach does not enable us to distinguish between the three aforementioned Treg 
subsets. In contrast, CD147 may be a better molecule for isolation of Tregs, as it helps to 
divide Tregs into their functional subsets, with aTregs being directly selected as 
CD25+CD147+ and rTregs as CD25+CD147- cells. Future experiments looking into Treg 
function could perhaps be based on CD147+Treg isolation instead of solely relying on CD25+ 
based methods.  
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Furthermore, the fact that CD147 represents an activated Treg subset with exceedingly 
suppressive properties makes it an interesting subject of study in clinical settings such as 
cancer, autoimmunity and tolerance to autotransplants. However, the distinctive Treg marker 
that sets Tregs completely apart from activated T cells still remains to be discovered, as 
CD147 is known to also be expressed on activated T cells. Explicit targeting of Tregs for 
interventional purposes thus continues to be a challenge. 
6.2 Anti-tumor immunity in ovarian carcinoma 
A large number (>1/3) of ovarian cancer patients present with malignant ascites at diagnosis, 
and mostly all develop ascites during relapse. The presence of malignant ascites relates to 
peritoneal spread of the disease, and is thus associated with poor outcome. 
Malignant ascites acts as a reservoir of soluble elements and cellular components which 
constitute a pro-inflammatory and tumor-promoting microenvironment for the malignant 
cells. In fact, ascites represents a rich tumor-friendly microenvironment which both promotes 
the growth and motility of tumor cells, and also contributes to inhibiting the response of 
chemotherapy. In other words, the ascites embodies a chief source of morbidity for OC 
patients. 
The fact that ascites is immunosuppressive is something that was first discovered in the 
1980’s. Several groups assessed the inhibitory effect of ascites on immune activation using 
different assays 178-181. We confirmed ascites induced-suppression of T cells with a CFSE 
analysis, something which has not been done before, and we discovered that the suppression 
was equal against self and non-self cells, in a concentration-dependent manner. These 
findings substantiate the fact that the tumor microenvironment is highly immunosuppressive 
in ovarian carcinoma patients. Despite the presence of antitumor immune cells, the immune 
system is unable to eradicate the tumor. As mentioned in the introduction, tumors employ a 
large number of mechanisms to achieve immunological escape. Among these are the 
recruitment and induction of Tregs, which are known to be present in the malignant ascites 
from OC patients, and the presence of which is known to correlate badly with patient 
outcome 81;182. Tregs suppress other cells through several mechanisms, including cell-to-cell 
contact, up-regulation of inhibitory molecules such as CTLA-4, and through secretion of 
immune inhibitory molecules such as PGE2 and IL-10 
23;32;182. After assessing whether ascites 
contains a soluble factor which is able to suppress T cell proliferation, we attempted to 
investigate the source of this inhibitory molecule. Our results indicate that ovarian cancer 
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tumor cells are not responsible for secretion of the inhibitory factor. This was tested both with 
cell-lines (SKOV-3) and inherent tumor cells isolated from ascites. As tumor cells were 
excluded as a potential source, some other cell-type which is abundant is ascites must be the 
responsible, and Tregs might possibly be the source. 
As the presence and possible origin of the inhibitory molecule was confirmed, further 
investigations were warranted. A recent multiplex profiling of cytokines in ascites 
demonstrated increased expression of several factors, including pro-inflammatory molecules 
such as IL-6, IL-8, IL-10. The presence of both IL-6 and IL-10 is also associated with poorer 
disease outcome in OC patients 183;184. IL-6 is known to promote tumor growth, invasion, 
migration, and angiogenesis and promote chemo resistance 185, while IL-10 is known to 
inhibit T cell proliferation, hamper dendritic cell maturation and inhibit T cell co-stimulatory 
molecules. It seems that the presence of IL-10 in ascites may contribute to tumor cells 
evading host immunological surveillance 186. Furthermore, it has been shown that the 
concentration of IL-6, IL-8 and IL-10 are significantly higher in the ascites of ovarian cancer 
patients compared to the levels in serum, and correlated with poor prognosis and lack of 
response to therapy. Furthermore, B7-molecules are known to be present in malignant ascites, 
and they are known as potential targets for immune modulating therapies 56;57;84;187. Another 
interesting target is PD-1, which has also been implicated in negative regulation of immune 
cells in ovarian carcinoma patients 188, and which can now be targeted with checkpoint 
inhibitors. 
We reported that cell-free ascites suppress T cell proliferation in a concentration-dependent 
manner. We tried to abolish ascites-induced suppression by blocking different immune 
inhibitory molecules which are known to be present in malignant ascites, including IL-6, IL-8, 
IL-10, PGE2, CTLA-4, B7-H1, B7-DC, PD-1 and PI3K. PI3K was chosen as it is a known 
mediator of the PGE2-patwhay 
126;189. Of the molecules tested, only antagonizing of PGE2 
showed some tendency to reduction in ascites-induced suppression, although none of the 
effects were significant. However, it is interesting to note that the aforementioned molecule 
that did show some effect is implicated in Treg-modulating pathways. It might be that it is 
not sufficient to target the molecules individually, but that a combined treatment leading to 
synergistic effect could be needed to achieve a proper reduction of ascites-induced 
immunosuppression. 
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Furthermore, we characterized a possibly suppressive factor in ascites as heat sensitive, partly 
in line with Sheid and Boyce 181. Other studies reveal the factor to possess heat-stable 
properties 178;179. In addition, we found suppression to be reversed after proteolytic enzyme 
digestion. On the contrary, a previous study revealed the inhibitory substance to be 
unaffected by protease treatment. A successful isolation attempt has previously been made 
with TCA precipitation, where the factor stayed soluble in TCA and showed an augmentation 
of suppressive activity 178. Our attempts to purify the factor with acetone precipitation 
however revealed that the factor is not to be found in the acetone precipitate. We also 
examined the supernatant, subsequent to heat-inactivation, a combined treatment that also 
reversed ascites’ suppressive action. 
 
The use of malignant ascites from ovarian carcinoma patients as a model to study anti-tumor 
immunity has both its benefits and disadvantages. On the one hand, malignant ascites 
contains all the constituents of the tumor microenvironment in a solution, including tumor 
cells, immune cells, fibroblast, cytokine etc. Cells in suspension are easily accessible for both 
isolation and further experiments, in particular with flow cytometry, which is the main 
experimental method used in this Thesis. Flow cytometry is based on laser detection of cells 
and molecules in suspension that are labelled with fluorescent antibodies targeting either 
surface or intracellular antigens. 
However, the ascites samples received for this study were quite heterogeneous in their nature 
both with regards to cell numbers, cell distribution and protein content. In order to perform 
reproducible experiments, it is required that the protocol remains somewhat constant. 
However, due to the variation in both cell count and dispersal, it was more often than not 
impossible to get adequate number of cells required for the experiments. In addition, on 
several occasions the ascites was not suitable for use in experiments, due to extensive 
coagulation most likely caused by high fibrin content. However, despite the heterogeneous 
nature of the malignant ascites, their immunosuppressive properties remained persistent 
throughout various experiments.  
Previous studies report characterization and isolation of inhibitory factor(s) in malignant 
ascites. However, the results from such characterizations vary, with some data being 
consistent with our own, while other findings are contradictory to what we found. The 
confirmation that ascites contains suppressive substance(s) is clinically relevant as it 
contributes to the understanding of how ovarian tumors can develop in the presence of host 
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immunity, and could possibly provide a much needed target for novel OC therapy. OC 
continues to be one of the most lethal malignancies, with an almost unchanged outcome in 
recent years. The future discovery of a specific immunosuppressive substance(s) might 
constitute the basis for future immune modulating therapy, where manipulation of host 
immunity can be used in treatment of OC patients. 
6.3 Improving treatment of colorectal cancer 
With increasing CRC incidences world-wide, there is an urgent need for improved surgical 
procedures and new chemotherapy and targeted therapy protocols, when the disease is 
established, but there is also a need to look into potential chemoprevention, both to reduce 
disease-development and progression. 
6.3.1 Aspirin 
Chemoprevention is an emerging science which refers to the use of agents that inhibit, delay 
or reverses carcinogenesis. Aspirin is among the most promising agents for CRC patients, 
with strong evidence from animal studies, experimental studies, observational studies and 
randomized controlled trials to support its use. 
In our cohort of 25,644 patients diagnosed with colorectal cancer, we had 6,109 patients that 
used aspirin regularly (> 3 prescriptions = 6 months regular use). The regular aspirin users 
had an average adherence of 0.99 defined daily dose (DDD), which virtually equals 1 
tablet/day during the time of follow-up. We have conducted the largest study of its kind to 
this date, and the quality of the data used is among the best in the world. 
In Paper III of this Thesis, we report that regular use of aspirin following diagnosis of CRC, 
results in a 16 % improved survival from colorectal cancer, and a 6 % increased overall 
survival. These findings are much in line with previous reports160-163;165;166;190-192. However, 
we were not able to stratify the data on known tumor molecular profiles such as PI3K-CA or 
K-Ras mutations or according to COX-2-expression levels, due to the nature of the registry 
material. It is well-known that COX-2 transcription is up-regulated in both human adenomas 
and CRC, which probably relates to APC mutations. Previous observational studies have 
looked at the benefit of aspirin use after CRC diagnosis in patients with COX-2 
overexpression and PI3K-CA mutations. Chan et al. showed that regular aspirin use was 
associated with a lower risk of colorectal cancer-specific mortality in patients harboring 
tumors with COX-2 overexpression, and another study by Liao et al., published in 2012, 
showed increased survival with post-diagnostic aspirin use in patients with mutated-PI3K-CA 
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colorectal cancer 160;192. On the other hand, Reimer et al. could not find a survival benefit 
neither with COX-2 over-expression nor PI3K-CA mutation, and Kothari et al. did not 
confirm an advantage of aspirin use in CRC patients harboring PI3K-CA mutations either 
162;193. However, these studies had significant weaknesses with regard to study size, which 
should be taken in to account when interpreting the results. Conversely, our study offers a 
large sample, but has limitations due to a lack of opportunity to adjust for these possibly 
predictive factors. It may be that aspirin is only or mostly useful for a selected group of CRC 
patients, with a particular molecular profile. But we were not able to look into that in our 
study. However, our study included more than twice as many study subjects as the previous 
studies, making our findings quite valuable. In addition, we were able to stratify the effect of 
aspirin to important factors such as differentiation grade, tumor site and stage. 
In our study we mainly assessed the effect of aspirin on CRC- and overall survival. However, 
we also adjusted for the use of NSAIDs and coxibs, in addition to other drugs that are known 
to affect CRC prognosis. The VICTOR trial used the COX-selective inhibitor, rofecoxib 
(VIOXX), which showed no benefit of its use after CRC diagnosis regardless of PI3K-
mutation status. However, adjuvant aspirin use was shown to be beneficial in PI3K-CA 
mutant CRC in the same study 194. The COX-2-specific inhibitor, celecoxib, was shown to 
promote caspase- and proteasome-dependent degradation of β-catenin, a crucial oncogenic 
transcription factor, in colon cancer cells, independent of COX-2 expression 195. Furthermore, 
sulindac (non-selective COX inhibitor) induced tumor regression in FAP patients, but didn't 
change the level of major prostaglandins in rectal mucosa 196 . Several in vitro studies also 
suggest the presence of COX-independent mechanisms, as both non-selective (NSAIDS, 
sulindac) and COX-2-selective inhibitors (celecoxib and rofecoxib, the latter with the highest 
COX-2 selectivity), have been shown to suppress proliferation rate, alter cell cycle 
distribution and induce apoptosis of colon cancer cell lines regardless of their COX-2 status. 
In addition, several studies show that the more COX-selective the NSAID/drug is, the more 
limited the anti-cancer effect becomes. Conventional NSAIDS such as sulindac and aspirin, 
reduce the number of intestinal polyps in FAP patients more efficiently than by COX-2-
selective inhibitors such as celecoxib 197;198.  
In addition to the COX-2 mediated CRC-protective effect conferred by aspirin, comes 
inhibition of COX-1 on platelets, which is believed to reduce metastasis. COX-1 leads to 
accumulation of thromboxane A2 (TXA2), which promotes platelet activation and 
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aggregation. Activated platelets can aggregate circulating tumor cells, and thus conceal them 
from recognition and killing by natural killer cells.  
Aspirin has a short half-life (about 2-3 hours at low dose, and 10-15 hours with high dose) 
when administered in vivo. At low doses aspirin nearly completely inhibits the capacity of 
COX-1 to activate TXA2, due to irreversible inhibition of COX-1 and the limited ability of 
anucleated platelets for de novo protein synthesis. This leads to profound inhibition of platelet 
function throughout the dose intervals (24h). COX-2 inhibition on the other hand, requires 
higher doses. However, much remains unknown about the exact mechanisms underlying the 
anti-tumor effects of aspirin. Most likely it is a combined effect of COX-1 and COX-2 
inhibition, but one cannot dismiss the possibility that the CRC protective effect of aspirin is 
due to COX-independent mechanisms.  
In Norway, enteric coated aspirin tablets are available on prescription either as 75 mg or 160 
mg. We refrained from using the dose in survival analysis because of several reasons. For 
instance, almost 20% of the aspirin exposed cases had received prescriptions for both doses. 
Furthermore, the indication for the different doses differs, with 75 mg being prescribed for 
cardiovascular protection, and 160 mg to prevent cerebral strokes. The latter group is often 
older and has more comorbidity. These differences could introduce biases that could account 
for the differences in outcome. Also, our study was not designed to assess a dose-response-
relationship, and thus we are careful to give any strong recommendations to dose.  
In addition, we stratified the aspirin exposed cases according to whether they began their 
aspirin use prior to CRC diagnosis and continued with it afterwards (pre- and post), or 
whether they solely used it after CRC diagnosis (post). Our results show that patients using 
aspirin pre- and post-diagnosis, have the most benefit of aspirin use (CSS HR, 0.75; 95% CI, 
0.69–0.82) and OS HR, 0.85; 95% CI, 0.80-0.91). However, it is important to note that the 
analysis has limitations, as we were only able to assess aspirin use from 2004. But the results 
remained the same when we stratified the material to look at aspirin use from 2004 and CRC 
diagnosis from 2005. In sum, our results show an advantage with pre- and post-diagnosis 
aspirin use, when compared with sole post-diagnosis aspirin use. On the other hand, 
McCowan, Chan and Bastiaanet et al. 160;161;166, show that patients taking aspirin prior to 
CRC diagnosis had a slightly less profound effect of aspirin on disease-specific and/or overall 
survival. 
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We addressed our hypothesis with an observational cohort study based on data linkage 
between two national registers of documented high quality, validity, completeness and 
comparability 199. Norway is privileged with a national health system with universal coverage, 
and all patients are identified through a distinctive 11-digit individual identification number. 
The ID-numbers provide a trustworthy means of tracking patients, and are a crucial 
foundation for the several nation-wide databases that collect health information on all 
inhabitants. For hospitals, pathological laboratories and general practitioners, it is mandatory 
to fill in structured template reports to the Cancer Registry of Norway (CRN), with 
information on localization, extent of disease and treatment. National Statistics Office 
(Statistics Norway) provides the CRN with information on cause of death notified on death 
certificates 199. All dispensed prescriptions are registered electronically, and automatically 
included into the Norwegian Prescription Database (NorPD). The NorPD has been functional 
since 2004, and includes information on patient (encrypted personal ID, birthdate, gender, 
place of residence), prescriber-ID and drug (strength, pharmaceutical form, pack size, number 
of packs, ATC-code, DDD, intended use, prescribed dose, price and dispensing date). 
However, drugs sold over the counter are not registered in the NorPD. Furthermore, NorPD 
undergoes monthly quality checks to ensure the validity of the data. The purpose of the 
NorPD has been to i) serve as resource for conducting record-linkage studies and ii) provide a 
sound evidence base for national decision-making with regards to drug utilization. 
 
Our study has several great advantages related to the data sources. For instance, unlike the 
reports by Chan et al. and Liao et al., that based the assessment of aspirin use on patient 
questionnaires, our study extracted data on aspirin use from a register with almost 99% 
coverage, where medication use is based on the established Anatomical Therapeutic 
Chemical (ATC) classification system, with daily defined dose (DDD) as a reliable unit of 
measurement 200.  This prevents recall bias and is a much more dependable and unbiased 
source of information. One of the advantages with using registry data is that it is a method of 
assured quality 199;201. Furthermore, the previously mentioned studies included selected study 
subjects (female nurses and male physicians), which may lead to selection bias due to 
inherent differences between the study subjects and the general population, which may not be 
accounted for in the study design. Our data on the other hand, included data on all patients 
diagnosed with CRC in the Norwegian population, all included in an unselective manner. 
This makes it easier to interpret and generalize the findings for the whole population, and not 
just for a highly selected subgroup. Furthermore, the assessment of both diagnosis 
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(morphology and topography) and cause of death, in the CRN is based on a transnational 
taxonomy method, the International Classification of Diseases for Oncology, 3rd edition 
(ICD-O3) and International Classification of Diseases, 10th edition (ICD-10), which further 
emphasizes the high quality and validity of the data. 
On the other hand, some are reluctant to base clinical decisions on sole observational studies. 
For instance, it is virtually impossible to know if the observed effect is due to some unknown 
or unadjusted for confounding factor.  
Our results are in line with previous reports regarding the potential benefits of aspirin to 
increase CRC-specific and overall survival in CRC patients. Considering the significant 
effect we report, and the limited side-effects of long-term aspirin use, especially when 
compared to conventional cancer remedies, the potential benefit of aspirin in this patient 
group is enormous. Also, from a cost-perspective, the use of aspirin is minimal compared to 
conventional chemotherapy. This further substantiates our findings. Aspirin use cannot be 
recommended on a general basis to all CRC patients quite yet, as more data is needed to 
further evaluate which patient group that benefits the most. And further evidence is needed 
from randomized controlled trials. 
6.3.2 Surgery 
An increasing number of patients diagnosed with colorectal cancer are presenting with either 
synchronous or metachronous metastases, with the liver being the main target organ. The 
reason for this is most likely because all venous blood from the intestine drain through the 
portal circulation to the liver, making the liver into a filter that prevents tumor cells from 
passing further. Hepatic disease accounts for two-thirds of CRC deaths, emphasizing the 
importance of multidisciplinary and multimodality treatment options for colorectal liver 
metastases (CRLM) 202. Metastatic disease was considered incurable just a few years ago, and 
patients with untreated liver metastasis until recently had an expected survival rate of < 6 
months. Today however, patients presenting with synchronous liver metastasis are in some 
instances able to achieve survival rates comparable to patients presenting solely with 
localized disease. In fact, recent year’s advances in surgical treatment have led to an increase 
in curable rates from 10% to 20-25% 203. The definition of resectability has also shifted from 
a focus on tumor characteristics (tumor number and size), to determination of whether both 
intrahepatic and extrahepatic disease can be completely resected and whether such an 
approach is appropriate from an oncologic standpoint for a given patient. 
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CRLM patients today have improved expected survival due to advances in modern 
chemotherapy and other adjuvant treatment remedies such as RFA and portal vein ligation 
(PVL), to mention a few. Treatment modalities that render patients eligible for future 
resection are strongly recommended, however if the patient is still deemed unresectable then 
other treatments that may lengthen disease-free and overall survival should be pursued. Even 
though cure cannot be achieved in all CRLM patients, it is highly beneficial to convert the 
cancer from rapidly progressing to a slow progressing or chronic state. This approach has 
improved the quality of life and time of survival in those that are not curable 204 
The anticipated 5-year survival rate after resection for CRLM is approximately 35%, and 
patients with disease initially determined to be anatomically unresectable can be offered 
neoadjuvant downsizing followed by resection of CRLMs to reach a comparable survival rate 
of > 50% 176. These findings are in line with our results, showing that patients receiving 
neoadjuvant chemotherapy to downsize the tumor load reached an overall long-term survival 
comparable to that of primary resectable patients. Furthermore, neoadjuvant chemotherapy 
serves incidentally as a tool for selecting patients with an optimal post-operative prognosis, as 
patients progressing during ongoing treatment most likely will not benefit from surgical 
treatment. These results support an aggressive treatment approach to metastatic CRC, as 
suggested by others. However, it is important to remember that morbidity increases with 
duration of neoadjuvant therapy, due to hepatotoxic effects of both oxalaplatin and 
fluorouracil 205, and in some instances other treatment modalities such as ablation and PVE 
should be considered. 
In Paper IV of this Thesis, we present data from a time period at Oslo University Hospital 
where several novel management strategies were applied to CRLM patients in an attempt to 
improve treatment and thus survival. These include neoadjuvant and adjuvant chemotherapy, 
two-stage surgery with portal vein embolization, laparascopic surgery, surgical techniques 
adapted from liver transplantation, technique and surgical tools adapted to limit blood loss, 
radio frequency ablation and re-resection for disease recurrence. In our study with 239 
patients with resectable liver metastasis, we compared outcome with respect to overall and 
disease-free survival in different subgroups based on established risk factor and the new 
modalities. Despite the small size of our cohort, the heterogeneity of the disease and between 
patients, we believe our material is interesting with respect to discussions regarding optimal 
treatment of CRLM. 
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Approximately two-thirds of patients have recurrence following resection of colorectal 
metastases. Our findings indicate that a second and third resection of recurring CRLMs 
should be considered when possible because the survival is the same after each resection. Our 
results are in line with previous reports that also indicate that resection should be assessed in 
patients with extrahepatic recurrences 206. Extrahepatic metastatic spread has previously been 
considered an end-stage-disease. However, in recent years, combined liver and lung resection 
has produced long-time survivors. But it is important to note that among extrahepatic 
metastatic sites, lung metastases have a superior survival to metastases located in pedicular 
lymph nodes or the peritoneum. In the material presented in Paper IV, six patients presented 
with concomitant liver and lung metastasis, and only one of them died of the progression of 
the lung manifestation that could not be handled surgically. In addition, it is interesting to 
note that patients resected for recurrent disease of the lung following hepatic resection, had 
comparable and perhaps even better survival compared to those repeatedly resected for 
recurrent disease of the liver. Accordingly, both pulmonary and non-pulmonary extrahepatic 
disease should be considered for surgical resection, as long as it is resectable or may become 
resectable after downsizing. In more recent years, a “liver first” approach, where liver 
metastases are removed initially, followed by primary tumor resection, has been promoted, 
but this was not considered in our material 207. 
The findings presented in this paper can be interpreted in light of two common ways to view 
systemic cancer development. On the one hand is the linear model, in which the primary 
tumor is regarded as the locomotive behind tumor advancement. The linear model advocates 
that development of malignant cells happens locally at the primary tumor site, and that these 
cells are further released in to the systemic circulation at a later time point. It is believed that 
as the tumor and disease progresses, it acquires increasingly aggressive biological features. 
On the other hand is the parallel model, which perceives the development of tumors as a 
corresponding course between the primary tumor and distant metastases. In light of this 
model, if the metastasizing process occurs at an early time point during the development of 
the primary tumor, the disease may not progress and become more aggressive at later stages 
208;209. The primary tumor may in fact possess aggressive metastasizing properties from the 
very commencement of its advance. And the primary tumor and its metastases may develop 
in parallel, gain different mutations and become more or less aggressive than the primary 
tumor due to varying conditions in the tumor microenvironment. 
63 
 
Hypothetically, in the parallel model, all the metastases that eventually will be found are 
already present at the time of diagnosis. Metastases in various organs may be manifestations 
of a process that has taken years to reach a level of detection, and as such, metastases may not 
be a sign of an explosive metastatic spread 210. In Paper IV of this Thesis we report mean 
time intervals from primary tumor to liver metastases and from liver metastases to 
presentations of recurrences in patients with resectable CRLM. The disease-free interval 
between each event is the same, and even though it is not firm evidence of the disease not 
becoming more aggressive, it is a curious finding. Furthermore, if the metastases that 
eventually present are already there at resection of primary disease, these patients may in fact 
have a better chance of cancer-specific survival after removal of every “new” disease 
recurrence as this may not represent firsthand disease manifestations, but the last remaining. 
In line with this, “recurrent disease” may be an incongruity as the disease may not be 
recurring, but continues to deliver earlier established metastases growing in parallel and 
reaching a size that allows detection at different time points following primary surgery. 
In reality it is most likely that metastases develop on both a linear and parallel scale and that 
metastatic disease is systemic or multifocal in its nature and may encompass unrecognized 
foci at the time of surgery, irrespective of the presentation at the time of diagnosis. This 
interpretation/view substantiates an aggressive treatment approach to induce resectable 
patients and perform repeated resections that continue to reduce tumor load. 
6.4 Perspectives 
There is a continuous interplay between a developing tumor and the immune system. In 
Paper I of this Thesis, we discovered a novel Treg surface marker that identifies a highly 
suppressive and activated subset. However, a totally specific Treg marker that sets the 
population completely apart from activated T effector cells, still remains to be found. This is 
vital to be able to target Tregs specifically for interventional purposes. In addition, we 
attempted to unravel some of the soluble mechanisms conveying immunosuppression in the 
tumor microenvironment in ovarian carcinoma. There is still a need to fully understand these 
mechanisms, to be able to target them for future immune-therapeutically purposes. 
Furthermore, in Paper III, we looked at the effect of post-diagnostic aspirin use in CRC 
patients, and found that it conveys a significant survival benefit. In light of these findings, we 
intend to do a randomized controlled trial in CRC patients with liver metastasis, which will 
64 
 
be randomly allocated in to receiving aspirin or placebo, following surgery, and followed-up 
for 3 years. 
In Paper IV, we highlight the effect of implementation of novel treatment strategies with 
respect to disease-free and overall survival in patients directly subjected to liver surgery or 
after downsizing to resectable CRLMs. Our report adds arguments to the ongoing discussions 
in the field, and substantiates the importance of aggressive treatment in these patients.  
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7 Conclusions 
 
I. The trans-membrane protein CD147 defines a subset of activated, highly suppressive 
regulatory CD4+CD25+ FoxP3+ T cells, and CD147 Treg subsets corresponds to 
CD45RA-based classification of Treg subsets 
 
II. Cell-free ascites from ovarian carcinoma inhibits T cell function in a dose-dependent 
manner, against self and non-self. However, the soluble mediator of immune 
inhibition in ascites is not secreted from intrinsic OC tumor cells or OC tumor cell-
lines. Furthermore, the inhibitory effect of ascites was not abolished when targeting 
known immune-modulating factors known to be present in malignant ascites, such as 
IL-6, IL-8, IL-10, PI3K, B7-DC, B7-H1, CTLA-1 and PGE2. 
 
 
III. Post-diagnostic aspirin in CRC patients is a strong and independent predictor for 
increased CRC-specific and overall survival. Furthermore, patients using aspirin 
before and after CRC diagnosis, have the most benefit with regards to survival. 
 
IV. Pre-operative chemotherapy is beneficial for patients with high tumor load of CRLM, 
as we show that these patients that receive neoadjuvant chemotherapy achieve 
oncologic results and life expectancy comparable to those that are primary resectable 
with low tumor load. Furthermore, following multiple resection, patients with 
recurrent CRLM achieve equal estimated survival as after primary resection. 
Recurrent disease in these patients present with similar time intervals as the primary 
tumor and subsequent metastasis. These findings indicate that recurrent disease may 
not be a sign of increasingly aggressive and progressive metastatic disease. 
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